

## Comprehensive Invited Review

# NAD<sup>+</sup>/NADH and NADP<sup>+</sup>/NADPH in Cellular Functions and Cell Death: Regulation and Biological Consequences

WEIHAI YING

*Reviewing Editors: Enrique Cadenas, Chandan K. Sen, Anthony Suave, and Michael Wolin*

- 
- I. Introduction
  - II. Metabolism of NAD and NADP
    - A. General information about NAD and NADP
    - B. NAD synthesis
    - C. NADP synthesis
    - D. Catabolism of NAD and NADP
    - E. Relationships between NAD and NADP
    - F. NAD transport across mitochondrial membranes
    - G. NAD transport across the plasma membranes of cells
  - III. Biological Functions of NAD and NADP
    - A. General information about the biological functions of NAD and NADP
    - B. NAD and NADP in antioxidation and oxidative stress
    - C. NAD and NADP in calcium homeostasis
    - D. NAD and NADP in energy metabolism and mitochondrial functions
    - E. Effects of NAD and NADP on gene expression
    - F. NAD and NADP in immunological functions
    - G. NAD and NADP in vascular activity
    - H. NAD and NADP in carcinogenesis and cancer treatment
    - I. NAD and NADP in aging
  - IV. NAD and NADP in Cell Death
    - A. PARP-1 and NAD in cell death
    - B. PARG in cell death
    - C. NAD in apoptosis
    - D. NAD in axonal degeneration
    - E. AIF and GADPH in cell death
    - F. NADP in cell death
  - V. Therapeutic Potential of NAD and NADP
    - A. Therapeutic potential of NAD<sup>+</sup> precursors
    - B. Therapeutic potential of NAD<sup>+</sup>
    - C. Therapeutic potential of NADH
    - D. Therapeutic potential of modulations of NADPH oxidase
  - VI. Conclusions

## ABSTRACT

Accumulating evidence has suggested that NAD (including NAD<sup>+</sup> and NADH) and NADP (including NADP<sup>+</sup> and NADPH) could belong to the fundamental common mediators of various biological processes, including energy metabolism, mitochondrial functions, calcium homeostasis, antioxidation/generation of oxidative stress, gene expression, immunological functions, aging, and cell death: First, it is established that NAD mediates energy metabolism and mitochondrial functions; second, NADPH is a key component in cellular antioxidation systems; and NADH-dependent reactive oxygen species (ROS) generation from mitochondria and NADPH oxidase-dependent ROS generation are two critical mechanisms of ROS generation; third, cyclic ADP-ribose and several other molecules that are generated from NAD and NADP could mediate calcium homeostasis; fourth, NAD and NADP modulate multiple key factors in cell death, such as mitochondrial permeability transition, energy state, poly(ADP-ribose) polymerase-1, and apoptosis-inducing factor; and fifth, NAD and NADP profoundly affect aging-influencing factors such as oxidative stress and mitochondrial activities, and NAD-dependent sirtuins also mediate the aging process. Moreover, many recent studies have suggested novel paradigms of NAD and NADP metabolism. Future investigation into the metabolism and biological functions of NAD and NADP may expose fundamental properties of life, and suggest new strategies for treating diseases and slowing the aging process. *Antioxid. Redox Signal.* 10, 179–206.

## I. INTRODUCTION

**N**ICOTINAMIDE ADENINE DINUCLEOTIDE (NAD<sup>+</sup>), reduced nicotinamide adenine dinucleotide (NADH), nicotinamide adenine dinucleotide phosphate (NADP<sup>+</sup>), and reduced nicotinamide adenine dinucleotide phosphate (NADPH) have been known as classic molecules involving in energy metabolism, reductive biosynthesis, and antioxidation (27, 29, 233). Structurally NADP<sup>+</sup> is identical to NAD<sup>+</sup> except for the additional 2' phosphate on the adenosine ribose moieties of NADP<sup>+</sup>. However, NAD (including NAD<sup>+</sup> and NADH) are mainly used by the enzymes that catalyze substrate oxidation, while NADP (including NADP<sup>+</sup> and NADPH) are mainly used by the enzymes that catalyze substrate reduction (233).

Increasing evidence has suggested that the pyridine nucleotides NAD and NADP have far more extensive biological functions than their classical functions (27, 29, 233, 328, 329). The following findings may be of particular interest: a) Recent studies have indicated pivotal roles of NAD<sup>+</sup>-dependent histone deacetylases (*i.e.*, sirtuins) in aging (35); b) poly(ADP-ribose) polymerase-1 (PARP-1)—a major NAD<sup>+</sup>-consuming enzyme—appears to mediate oxidative cell death under many conditions (296, 328); c) cyclic ADP-ribose and nicotinic acid adenine dinucleotide phosphate (NAADP)—two endogenous molecules generated from NAD<sup>+</sup>—are key signaling molecules mobilizing intracellular calcium stores (159, 160); and d) NADPH oxidase is a major generator of reactive oxygen species (ROS) in both immunological reactions and multiple diseases (26). These seemingly diverse topics of biomedical research are fundamentally linked by NAD and NADP. In recent years there have also been a number of novel findings regarding the metabolism of NAD and NADP. For examples, three isoforms of nicotinamide mononucleotide adenylyltransferases (NMNATs)—the key NAD<sup>+</sup>-synthesizing enzymes—have been found in various subcellular organelles (30, 182, 235); and novel pathways by which NADH and NADPH are generated have also been found (30, 102, 221). Collectively, these findings have strongly suggested the necessity to search for novel paradigms about the metabolism and biological functions of

NAD and NADP, which may be required for exposing the fundamental mechanisms in biology as well as the essential relationships among various biological and pathological processes.

## II. METABOLISM OF NAD AND NADP

## A. General information about NAD and NADP

Intracellular levels of NAD are significantly higher than those of NADP under physiological conditions (233). Because it is generally believed that mitochondrial membranes are impermeable to NAD and NADP (82, 83, 164, 233), there are two major pools of NAD and NADP in cells: the cytosolic pool and the mitochondrial pool. However, cytosolic reducing equivalents of NADH can be shuttled into mitochondria by the NADH shuttles, which maintain the NADH homeostasis in cytosol (195). The mitochondria pool of NAD<sup>+</sup> represents a significant portion of the total NAD<sup>+</sup> pool in myocytes (82). However, there is no sufficient information about the percentage of mitochondrial NAD<sup>+</sup> in the total pools of NAD<sup>+</sup> in other cell types. It has been reported that mitochondrial permeability transition (MPT) pore opening in myocytes can lead to mitochondrial NAD<sup>+</sup> release and subsequent hydrolysis of NAD<sup>+</sup> by NAD<sup>+</sup> glycohydrolase (82). A recent study has also suggested that MPT mediates the PARP-1 activation-induced mitochondrial NAD<sup>+</sup> loss of mouse neurons and astrocytes (7), which may significantly contribute to metabolic dysfunction (271). Due to the critical roles of NAD and NADP in cellular functions and cell death, it is of great interest to further determine the relationships between cytosolic NAD/NADP and mitochondrial NAD/NADP.

Under physiological conditions, the ratio of cytosolic free NAD<sup>+</sup>/NADH is ~ 700 to 1 (276, 294, 342), while the mitochondrial NAD<sup>+</sup>/NADH ratio has been reported to be 7–8 (276, 294). In contrast, the levels of NADPH are much higher than those of NADP<sup>+</sup> (122, 233). Cumulating evidence has suggested that cytosolic free NAD<sup>+</sup>/NADH ratios are altered under various pathological conditions. For example, in diabetic

tissues there are sorbitol pathway-mediated decreases in  $\text{NAD}^+/\text{NADH}$  ratios (122, 207), which may play a crucial role in the pathogenesis of diabetic complications (122). Because the ratios of  $\text{NAD}^+/\text{NADH}$  and  $\text{NADP}^+/\text{NADPH}$  can affect numerous enzymatic activities and MPT (352) which play important roles in cell death under many conditions (69, 150, 165), it is warranted to further determine the changes of these ratios under both physiological and pathological conditions.

### B. NAD synthesis

$\text{NAD}^+$  biosynthesis plays a central role in the metabolism of NAD and NADP, because  $\text{NAD}^+$  is necessary for the generation of NADH,  $\text{NADP}^+$ , and NADPH. Two known  $\text{NAD}^+$  biosynthesis pathways are the *de novo* pathway and the salvage pathway (181, 182). Nicotinamide and nicotinic acid are the  $\text{NAD}^+$  precursors in the salvage pathway (30, 181, 182), which are first transferred onto phosphoribosyl pyrophosphate by phosphoribosyl transferases to form nicotinamide mononucleotide (NMN) or nicotinic acid mononucleotide (NaMN), respectively. Subsequently NMN and NaMN are converted by NMNATs to  $\text{NAD}^+$  and NaAD, respectively. NaAD is then amidated by  $\text{NAD}^+$  synthase to generate  $\text{NAD}^+$ . There are distinct differences between the salvage pathway of mammals and that of yeast and invertebrates (238). Mammals use nicotinamide instead of nicotinic acid as the main precursor for  $\text{NAD}^+$  synthesis: Nicotinamide is directly converted by nicotinamide phosphoribosyltransferase (Nampt) to NMN that is subsequently used by NMNATs for  $\text{NAD}^+$  generation (238). In contrast, in yeast and invertebrates nicotinamide can not be used directly for  $\text{NAD}^+$  synthesis before its conversion to nicotinic acid (238).

Quinolinic acid is the  $\text{NAD}^+$  precursor in the *de novo* pathway, which is generated from either L-tryptophan in animals and some bacteria, or L-aspartate in some bacteria and plants (135). Quinolinic acid is converted by quinolinic acid phosphoribosyltransferase to NaMN, which is subsequently converted to  $\text{NAD}^+$  by NMNATs and  $\text{NAD}^+$  synthase (233).

The nuclear enzyme NMNAT-1 is a key enzyme in both the *de novo* pathway and the salvage pathway of  $\text{NAD}^+$  synthesis (29), which had been the only known NMNAT until recently. It has been reported that the loss of NMNAT-1 in *Drosophila* leads to rapid and severe neurodegeneration that can be ameliorated by blockage of neuronal activity (340). A latest study has also found that NMNAT-1 can bind the poly(ADP-ribose) (PAR) on activated PARP-1 and promote poly(ADP-ribose)ylation (31). Protein kinase C-mediated phosphorylation of NMNAT-1 can lead to decreased binding of NMNAT-1 to PAR (31). This close interaction between a key  $\text{NAD}^+$ -synthesizing enzyme and a key  $\text{NAD}^+$ -consuming enzyme is intriguing, since it implicates potential coordination between  $\text{NAD}^+$  generation and  $\text{NAD}^+$  consumption in the nucleus. It has also been found that the gene product of human homolog of NMNAT-1 constitutes a major portion of the chimeric protein that mediates the delay in Wallerian neurodegeneration of Wld(S) mice (14, 182), suggesting a potential role of NMNAT-1 in axonal degeneration (14, 302). Recent studies have indicated the presence of three isoforms of human NMNATs—NMNAT-1, NMNAT-2, and NMNAT-3 (30, 182, 235), which are located in the nucleus, the Golgi complex, and mitochon-

dria, respectively (30, 182, 235). These findings, together with the observations indicating the presence of tankyrase in Golgi complex (54) and  $\text{NAD}^+$ -consuming enzymes in mitochondria (82, 85, 172), suggest that there are relatively independent machineries of NAD metabolism in the nucleus, the Golgi complex, and mitochondria.


Recent studies have indicated multiple novel and interesting properties of Nampt—another key enzyme in  $\text{NAD}^+$  synthesis: it has been demonstrated that three seemingly different proteins—Nampt, the presumptive cytokine pre-B-cell colony-enhancing factor (PBEF), and a new visceral fat-derived hormone visfatin—are actually the same protein (95, 188, 237, 241). The presence of Nampt/PBEF/visfatin in plasma raises an intriguing possibility that this protein might generate NMN extracellularly using the nicotinamide in plasma as a substrate, which may be subsequently transported into cells for NMNAT-catalyzed  $\text{NAD}^+$  synthesis (238). While many future studies are needed to demonstrate this hypothesis, our understanding regarding  $\text{NAD}^+$  synthesis could be significantly revised if this hypothesis were demonstrated: The processes of  $\text{NAD}^+$  synthesis may not only occur intracellularly in the nucleus and other subcellular organelles, but also occur extracellularly. It has also been proposed that the cytokine-like functions of PBEF and the insulin-mimetic functions of visfatin may be accounted for by the  $\text{NAD}^+$ -synthesizing functions of Nampt (238). Demonstration of this hypothesis would further deepen our understanding about the biological functions of the extracellular metabolic intermediates in  $\text{NAD}^+$  synthesis. Figure 1 provides diagrammatic presentation of the  $\text{NAD}^+$  metabolic machineries in cells.

It is noteworthy that the kynurenine pathway leads to generation of several neuroactive intermediates, including quinolinic acid, kynurenic acid, and 3-hydroxykynurenine (206, 249, 255). Thus, the kynurenine pathway has been a target for treatment of multiple neurological diseases (206, 249, 255). Increasing evidence has also suggested significant biological activities of nicotinamide and nicotinic acid—two important components in  $\text{NAD}^+$  metabolism: Nicotinic acid can significantly affect brain functions by such pathways as inducing glutamate release (301); and nicotinamide can also enhance energy metabolism, inhibit PARPs and sirtuins, and activate Akt (145, 168, 183, 312). A number of studies have also suggested therapeutic potential of nicotinamide for multiple diseases such as cerebral ischemia (19, 145, 183, 191). Recently it has been found that nicotinamide riboside—a novel  $\text{NAD}^+$  precursor in eukaryotes—can significantly extend the replicative lifespan of yeast (28).

A recent study has suggested a novel pathway for NADH generation: NADH may be directly generated from reduced form of NMN and ATP by NMNAT-2 and NMNAT-3, but not NMNAT-1 (30). It is warranted to further determine the physiological significance of this pathway.

### C. NADP synthesis

There are two major mechanisms by which  $\text{NADP}^+$  can be formed:  $\text{NADP}^+$  can be generated *de novo* from  $\text{NAD}^+$  through the action of  $\text{NAD}^+$  kinases (NADKs) (166); and  $\text{NADP}^+$  can also be formed from NADPH by multiple NADPH-dependent enzymes such as glutathione reductase (233). There are also two major mechanisms by which NADPH can be formed: The



**FIG. 1. NAD<sup>+</sup> metabolism in cells.** NAD<sup>+</sup> metabolism occurs both intracellularly in various subcellular organelles and extracellularly. The key NAD<sup>+</sup> synthesizing enzymes NMNAT-1, NMNAT-2, and NMNAT3 are located at the nucleus, the Golgi complex, and mitochondria, respectively. There are NAD<sup>+</sup>-consuming enzymes in these organelles, including poly(ADP-ribose) polymerase-1 (PARP-1), PARP-2, and certain sirtuins in the nucleus, tankyrase in the Golgi complex, and NAD<sup>+</sup> glycohydrolases in mitochondria. On plasma membranes, mono(ADP-ribosyl) transferases (ARTs) and ADP-ribosyl cyclases (ARCs) produce mono(ADP-ribosylation) on target proteins and generate cyclic ADP-ribose, respectively. Nicotinamide phosphoribosyltransferase (Nampt) may exist extracellularly and produce its biological effects by generating nicotinamide mononucleotide from nicotinamide.

first is that NADPH is generated from NADH and NADP<sup>+</sup> by mitochondrial transhydrogenase; and the second is that NADPH is generated from NADP<sup>+</sup> by multiple NADP<sup>+</sup>-dependent enzymes.

NADKs play a critical role in determining the levels of NADP, since the enzymes are the sole enzymes that can *de novo* generate NADP<sup>+</sup>. Thus, elucidation of the mechanisms underlying the regulation of NADKs is critical for understanding the regulation of NADP levels. Essential roles of NADKs in various biological activities of both prokaryotes and eukaryotes have been reported (105, 233, 264). Whereas three isoforms of NADKs have been found in yeast, there is only one known NADK in mammals (233).


There are four known groups of enzymes that catalyze NADPH formation from NADP<sup>+</sup> in cells: First, glucose-6-phosphate dehydrogenase and 6-gluconate phosphate dehydrogenase—two enzymes in the pentose phosphate pathway (also called ‘hexose monophosphate shunt’); second, cytosolic and mitochondrial NADP<sup>+</sup>-dependent isocitrate dehydrogenases (IDPc and IDPm) (201); third, cytosolic and mitochondrial NADP<sup>+</sup>-dependent malic enzymes (MEPc and MEPm); and fourth, mitochondrial transhydrogenase (246).

In cytosol, NADPH can be generated by glucose-6-phosphate dehydrogenase, 6-gluconate phosphate dehydrogenase, IDPc,

or MEPc (162, 180, 315). It has been reported that in yeast cytosolic acetaldehyde dehydrogenase also mediates NADPH generation from NADP<sup>+</sup> (102). In mitochondria NADPH can be generated from NADP<sup>+</sup> by IDPm, MEPm, or transhydrogenase (127). Figure 2 shows the pathways by which NADPH is generated in cytosol and mitochondria.

Glucose-6-phosphate dehydrogenase is a key enzyme for NADPH generation (146). While it is long thought as a ‘house-keeping’ enzyme present in all cell types, the enzyme can also undergo tissue-specific regulation by various factors, including oxidative stress, hormones, and nutrients (146). Although glucose-6-phosphate dehydrogenase is the most well-studied enzyme for NADPH synthesis, some studies have also suggested significant contributions of IDPc and MEPc to cytosolic NADPH synthesis and cellular antioxidation capacity (162, 180).

Mitochondrial transhydrogenase is located in the inner membranes of animal mitochondria, which couples the translocation of protons across mitochondrial membranes to the transfer of reducing equivalents between NAD(H) and NADP(H) (127). Under most physiological conditions, the enzyme is driven toward the reduction of NADP<sup>+</sup> by NADH via utilization of mitochondrial transmembrane electrochemical gradient of proton (246). Recent studies using transhydrogenase-knockout mice



**FIG. 2. Pathways by which NADPH is generated in cytosol and mitochondria.** In cytosol NADP<sup>+</sup> is generated from NAD<sup>+</sup> by NAD<sup>+</sup> kinase (NADK). NADPH can be generated from NADP<sup>+</sup> by glucose-6-phosphate-6-phosphate dehydrogenase (G6PDH), 6-glyconate phosphate dehydrogenase (6GPDH), cytosolic NADP<sup>+</sup>-dependent isocitrate dehydrogenase (IDPc), or cytosolic NADP<sup>+</sup>-dependent malic

enzymes (MEPc). In mitochondria NADP<sup>+</sup> is generated from NAD<sup>+</sup> by NAD<sup>+</sup> kinase, and NADPH can be generated from NADP<sup>+</sup> by mitochondrial NADP<sup>+</sup>-dependent isocitrate dehydrogenase (IDPm), mitochondrial NADP<sup>+</sup>-dependent malic enzymes (MEPm), or mitochondrial transhydrogenase (TH).

have indicated that deletion of the gene can lead to type II diabetes (94), which raises the question why the transhydrogenase deletion selectively impairs insulin secretion.

Whereas multiple enzymes can generate NADPH, the relative contribution of these enzymes to the general NADPH production in cells can be variable in different cell types or under different conditions. It has been suggested that at least for brain mitochondria, all of the three mitochondrial enzymes that can generate NADPH contribute to the mitochondrial NADPH generation and the reduction of oxidized glutathione in mitochondria (297). A significant role of IDPm in cellular antioxidation capacity has also been shown in NIH3T3 cells (162). Recent studies have suggested that at least in certain mammalian cells IDPm is a major source of mitochondrial NADPH, which can be inhibited by lipid peroxidation products (313) and regulated by  $\text{Ca}^{2+}$  (275). It has also been found that ROS can induce IDPm expression (130).

In yeast, Outten *et al.* found a novel NADPH-generating pathway—the NADH kinase-dependent pathway for NADPH generation (221): the POS5 gene product Pos5p has NADH kinase activity that generates NADPH by catalyzing phosphorylation of NADH, which appears to be a major NADPH-generating enzyme in yeast (221). Disruption of *POS5* led to a 50-fold increase in the mitochondrial mutation rate in yeast (264). However, it is unclear if similar mechanisms also exist in high eukaryotes.

#### D. Catabolism of NAD and NADP

$\text{NAD}^+$  can be consumed by multiple families of enzymes, including PARPs, sirtuins, ADP-ribosyl cyclases, and mono(ADP-ribosyl) cyclases, leading to generation of nicotinamide and other products containing ADP-ribose as the core structural component. The reactions catalyzed by these  $\text{NAD}^+$ -dependent enzymes can profoundly affect various biological processes. The major  $\text{NAD}^+$ -consuming enzymes include:

First, PARPs are a family of enzymes that consume  $\text{NAD}^+$  to produce PAR on target proteins (296). PARP-1 has been the most intensively studied member of PARP family, which appears to play important roles in regulation of various cellular and subcellular processes, including DNA repair, gene expression, genomic stability, cell cycle, and cell death (254, 296, 328). PARP-1 has also been shown to mediate multiple biological functions of tissues and organs, such as inflammation and learning and memory (44,296). Excessive PARP-1 activation has been found to mediate ischemic injuries of various organs, diabetes, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism, traumatic brain injury, hypoglycemic brain damage, and shock (296, 328).

Second, bifunctional ADP-ribosyl cyclases/cyclic ADP-ribose hydrolases can consume  $\text{NAD}^+$  to generate cyclic ADP-ribose as well as hydrolyze cyclic ADP-ribose into free ADP-ribose (347). The mammalian ADP-ribosyl cyclase CD38 is of particular interest: This enzyme could be a major regulator of intracellular  $\text{NAD}^+$  concentrations under physiological conditions (4); and CD38-generated cyclic ADP-ribose could play critical roles in many biological processes (159, 160, 329).

Third, the  $\text{NAD}^+$ -dependent histone deacetylases (or called Sir2 family proteins or sirtuins) produce deacetylation of both histones and nonhistone proteins by consuming  $\text{NAD}^+$ . This

process could profoundly affect aging, carcinogenesis, and cell death (79, 250).

Fourth, mono(ADP-ribosyl)transferases (ARTs) are a family of enzymes that consume  $\text{NAD}^+$  to produce mono(ADP-ribosyl)ation of proteins (64, 81). Recent studies have suggested that ART1-5 are expressed in various cell types (63, 261). Notably, the ecto-enzyme ART2 on the plasma membranes of Treg cells—a subset of T cells that mediates immunological activities—can produce mono(ADP-ribosyl)ation of P2X<sub>7</sub> receptors resulting in apoptosis of Treg cells (17, 147).

There is increasing evidence suggesting that CD38 could mediate intracellular  $\text{NAD}^+$  levels under physiological conditions, while PARP-1 could mediate intracellular  $\text{NAD}^+$  levels when significant DNA damage occurs: A recent study reported that there are significant increases in the tissue levels of  $\text{NAD}^+$  in CD38 knockout mice compared with wild-type mice (4). The extent of the increases is tissue-dependent, ranging from 2-fold (kidney) to 25-fold (heart). These results suggest that CD38 is a fundamental regulator of  $\text{NAD}^+$  levels under physiological conditions (4). It has also been established that PARP-1 mediates  $\text{NAD}^+$  depletion when significant DNA damage occurs (74, 329), while there is no significant difference between the  $\text{NAD}^+$  levels in the brains of PARP-1 knockout mice and the brains of wild-type mice under physiological conditions (88).

The major known  $\text{NADP}^+$ -degrading enzyme is  $\text{NAD(P)}^+$  nucleosidase that degrades  $\text{NADP}^+$  to ADP-ribose(2'-phosphate) and nicotinamide (182).  $\text{NADP}^+$  could also be converted to NAADP—an important regulator of intracellular calcium stores (96, 159, 160). While increasing evidence has indicated that  $\text{NAD}^+$  can be consumed through many pathways, thus producing various major biological effects, it remains unknown if  $\text{NADP}^+$  may also be catabolized through multiple pathways.

#### E. Relationships between NAD and NADP

Two enzymes, NADKs and mitochondrial transdehydrogenase, are essential for regulating the conversion between NAD(H) and NADP(H): NADKs are the sole enzymes catalyzing the generation of  $\text{NADP}^+$  from  $\text{NAD}^+$ , while it can not catalyze the conversion between NADH and NADPH (194); in contrast, transhydrogenase catalyzes the generation of ( $\text{NADPH} + \text{NAD}^+$ ) from ( $\text{NADP}^+ + \text{NADH}$ ). Due to the critical biological functions of NAD and NADP, NADKs and transhydrogenase could produce profound effects on cellular functions through its effects on the balance between NAD pool and NADP pool.

It has been reported that NADKs can be regulated by multiple factors: NADKs can be inhibited by such factors as NADH and NADPH (339), and activated by such factors as calcium/calmodulin (9,65). It is particularly interesting that oxidative stress (41, 105) and calcium/calmodulin can activate NADKs (9, 65), considering the established critical roles of oxidative stress and calcium/calmodulin in numerous biological and pathological processes (113, 190, 291, 318, 321, 322). Future studies are certainly warranted to further determine the regulation of these enzymes, and to determine the biological consequences of the regulation.

There are studies suggesting that the total levels of ( $\text{NAD} + \text{NADP}$ ) could be increased under certain conditions: It was found that fasting led to increased  $\text{NAD}^+$  levels by 33% in liver,

which returned to control levels by refeeding (240); serum withdrawal also induced increased PBEF expression in smooth muscle cells, which can lead to increased intracellular  $\text{NAD}^+$  levels (292); and pyridine nucleotide synthesis was also induced by mitogens (32). Moreover, it was reported that the total NADP levels were significantly increased in phorbol myristic acetate-treated human neutrophils (306).

### F. NAD transport across mitochondrial membranes

It is generally believed that mitochondrial inner membranes are not permeable to NAD (286). However, this belief has been challenged by several studies: Two mitochondrial  $\text{NAD}^+$  transporters, named Ndt1p and Ndt2p, have been found to import  $\text{NAD}^+$  into the mitochondria of *Saccharomyces cerevisiae* (282); intact plant mitochondria can uptake  $\text{NAD}^+$  in a concentration-dependent and temperature-dependent manner (215, 281); and there was  $\text{NAD}^+$  influx into the mitochondrial matrix of cultured human cells harvested under quiescent conditions, when external  $\text{NAD}^+$  was added to the digitonin-permeabilized cells (244).

Whereas mitochondrial inner membranes could be impermeable to NADH, the reducing equivalents of cytosolic NADH can be shuttled into mitochondria by NADH shuttles, including the malate—aspargate shuttle and the glycerol-3-phosphate shuttle (195). The major components of the malate—aspargate shuttle include cytosolic malate dehydrogenase, aspartate transaminase, mitochondrial aspartate—glutamate carrier, and mitochondrial malate dehydrogenase. The glycerol-3-phosphate shuttle is composed of cytosolic glycerol-3-phosphate dehydrogenase and mitochondrial glycerol-3-phosphate dehydrogenase.

The levels of cytosolic NADH can be regulated by not only the NADH shuttles, but also the lactate dehydrogenase-catalyzed pyruvate—lactate conversion and other dehydrogenase-catalyzed reactions (195). Due to the critical roles of these pathways in energy metabolism and other biological functions, the NADH shuttles may profoundly affect cellular functions due to its impact on cytosolic NADH. It is also conceivable that alterations of the NADH shuttles may produce major pathological consequences.

Several recent studies have used the malate—aspargate shuttle- or the glycerol-3-phosphate shuttle-deficient mice to determine the biological functions of the NADH shuttles. A recent study provided critical information regarding the regulation of NADH shuttles in neurons (224): Because ARALAR—the neuronal  $\text{Ca}^{2+}$ -binding mitochondrial aspartate—glutamate carrier—plays a role in the malate—aspargate shuttle and has  $\text{Ca}^{2+}$  binding domains facing the extramitochondrial space, the researchers determined the effects of  $\text{Ca}^{2+}$  signals on the NADH shuttling activity. The study indicated a novel mechanism by which small  $\text{Ca}^{2+}$  signals that are below the levels to activate  $\text{Ca}^{2+}$  uniporters affect mitochondrial NADH levels: the small  $\text{Ca}^{2+}$  signals can enhance NADH shuttling from cytosol to mitochondria by activating ARALAR. It is of interest to further determine the post-translational regulation of the NADH shuttles under both physiological and pathological conditions.

### G. NAD transport across the plasma membranes of cells

It had been generally thought that  $\text{NAD}^+$  and NADH can not be transported across the plasma membranes of any cell types. However, recent studies have suggested that  $\text{NAD}^+$  and NADH can be transported across the plasma membranes of at least certain types of cells: Connexin 43 hemichannels could allow gradient-dependent  $\text{NAD}^+$  flux across fibroblast plasma membranes (42); and the studies by us and other researchers have also suggested that  $\text{NAD}^+$  can be transported across the plasma membranes of astrocytes (5, 295, 326).

Our latest study has provided the first evidence suggesting that NADH can be transported across the plasma membranes of astrocytes, which is mediated by  $\text{P2X}_7$  receptors (177): we found that treatment of astrocytes with  $10\ \mu\text{M}$ — $10\ \text{mM}$  NADH significantly increased intracellular NADH and  $\text{NAD}^+$ . Three lines of evidence have suggested that the NADH transport is mediated by purinergic  $\text{P2X}_7$  receptors: the  $\text{P2}$  receptor antagonist pyridoxal phosphate-6-azophenyl-2',4'-disulphonic acid abolished the NADH transport; RNA silencing-produced reductions of  $\text{P2X}_7$  receptors also decreased the NADH transport; and transfection of  $\text{P2X}_7$  receptor-deficient HEK293 cells with mouse  $\text{P2X}_7$  receptor cDNA increased the NADH transport in the cells. Collectively, our study provides the first direct evidence demonstrating that NADH can be transported across the plasma membranes of certain cell types by a  $\text{P2X}_7$  receptor-mediated mechanism. Our study also suggests a new approach for manipulating intracellular NADH and  $\text{NAD}^+$  levels. Future studies are needed to determine if NADH can also be transported across the plasma membranes of other cell types, and if pathological conditions can alter the NADH transport.

## III. BIOLOGICAL FUNCTIONS OF NAD AND NADP

### A. General information about the biological functions of NAD and NADP

While it has been long thought that the major biological functions of NAD are modulating cellular energy metabolism, increasing evidence has suggested that NAD also mediates cell death (5, 296, 326) and various major biological activities such as calcium homeostasis (29, 347) and gene expression (245, 342). Growing evidence has further indicated significant roles of NAD in such important biological processes as aging, carcinogenesis, and immunological functions (29, 35).

The major biological functions of NADPH are three fold: the first is to act as a key component in cellular antioxidation systems; the second is to act as an electron source for reductive synthesis of fatty acids, steroids, and DNA (233); and the third is to act as the substrate for NADPH oxidase that plays key roles in many biological and pathological processes by generating ROS.

Recent studies have suggested distinct biological functions of the multiple NADPH-generating machineries: While both IDPc and IDPm play a significant role in defending oxidative damage (130), IDPc also mediates lipid metabolism (148). The

sources of NADPH generation may determine the biological effects of NADPH: The NADPH generated by the mitochondrial enzymes could mainly contribute to mitochondrial antioxidation and biosynthesis, while the NADPH generated by the cytosolic enzymes may also contribute to NADPH oxidase-dependent ROS generation when NADPH oxidase is activated.

The major known biological function of NADP<sup>+</sup> is acting as the precursor for NADPH formation. NADP<sup>+</sup> could also be a precursor for generation of NAADP—an endogenous molecule that can mobilize acidic intracellular calcium stores (96, 159, 160). NAADP and cyclic ADP-ribose—two molecules generated from NADP<sup>+</sup> and NAD<sup>+</sup>—have emerged as important regulators of calcium homeostasis.

*B. NAD and NADP in antioxidation and oxidative stress*


PARP-1 plays a key role in oxidative cell death under many conditions (296, 328). Increasing evidence has suggested that NAD<sup>+</sup> depletion mediates PARP-1-induced cell death (5, 326–329). NAD may also affect antioxidation and generation of oxidative stress through several pathways: First, the NADH/NAD<sup>+</sup> ratio is an index of cellular reducing potential, since the redox couple plays key roles in numerous redox reactions and has one of the most negative reduction potential (−0.32 V) in cells; second, NAD<sup>+</sup> can be converted by NADKs to NADP<sup>+</sup>—the precursor for NADPH formation (194); third, some studies have suggested direct antioxidation effects of NADH (144, 192, 220); and fourth, NAD<sup>+</sup> can inhibit ROS generation from α-ketoglutarate dehydrogenase and pyruvate dehydrogenase as well as permeabilized rat brain mitochondria (274). Seemingly paradoxically, excessive intracellular NADH can produce ‘reductive stress’, which may result from its capacity to induce release of ferrous iron from ferritin (128), or from the capacity of xanthine oxidase/xanthine dehydrogenase to generate ROS by oxidizing NADH (344).

NADPH is one of the most important factors in cellular antioxidation through the following pathways: first, NADPH is required for regeneration of GSH from GSSG through the action of glutathione reductase. GSH is essential for the functions of several key antioxidation enzymes including glutathione peroxidase and glutathione S-transferases (309). Second, at least in some cell types, a large portion of NADPH binds the important H<sub>2</sub>O<sub>2</sub>-disposing enzyme catalase (143), which reactivates catalase when catalase is inactivated by H<sub>2</sub>O<sub>2</sub>. Third, NADPH is also an essential component in another important antioxidation system—the thioredoxin system (15).

A crucial role of the pentose phosphate pathway in defending oxidative stress has been reported by multiple studies (223, 269). For example, in a study that used male mouse embryonic stem cells with genetic inhibition of glucose-6-phosphate dehydrogenase, glucose-6-phosphate dehydrogenase appears to be essential in defending oxidative stress but is dispensable for pentose synthesis (223). Whereas it is widely accepted that NADPH mediates cellular antioxidation mainly through its effects on GSH regeneration, it has been reported that in red blood cells, NADPH plays a significantly more important role than GSH in defending oxidative insults (258), possibly due to the capacity of NADPH in reactivating catalase. A key role of glucose-6-phosphate dehydrogenase in NADPH synthesis and an-

tioxidation has been further indicated by the findings that the red cells from the patients of glucose-6-phosphate dehydrogenase deficiency have increased sensitivity to oxidative stress (268). Recent studies have also established important roles of IDPm in defending oxidative stress: overexpression and decreased expression of the enzyme leads to decreased or increased sensitivity of mitochondria to oxidative stress, respectively (130). It has also been reported that IDPc plays a significant role in cellular antioxidation capacity (163). Figure 3 shows the pathways by which NADPH can decrease oxidative stress in cells.

Because mitochondrial transhydrogenase mediates the coupling of the H<sup>+</sup> translocation across mitochondrial membranes to the transfer of reducing equivalents between NAD(H) and NADP(H), it is tempting to propose that this enzyme may coordinate the activity of the tricarboxylic acid (TCA) cycle and the reducing potential of mitochondria: Increased TCA cycle activity can lead to increased NADH generation, which could both increase the H<sup>+</sup> gradient across mitochondrial membranes and potentiate ROS generation from the electron transport chain. Through transhydrogenase, an elevated H<sup>+</sup> gradient could lead to increased NADPH generation and increased antioxidation capacity of mitochondria. It is expected that inacti-



**FIG. 3. Effects of NADPH on cellular antioxidation capacity.** NADPH can be generated by glucose-6-phosphate dehydrogenase (G6PDH), 6-glyconate phosphate dehydrogenase (6GPDH), NADP<sup>+</sup>-dependent isocitrate dehydrogenases (IDPs), NADP<sup>+</sup>-dependent malic enzymes (MEPs), and transhydrogenase (TH). NADPH can increase cellular antioxidation capacity by acting as a substrate for glutathione reductase (GR) to reduce GSSG to GSH that is required for the activities of the antioxidation enzymes glutathione peroxidase (GPx) and glutathione-S-transferases (GST). NADPH can also increase antioxidation capacity by reactivating H<sub>2</sub>O<sub>2</sub>-inactivated catalase (CAT), and by promoting thioredoxin reductase (TrxR)-mediated regeneration of thioredoxin.

vation of this enzyme under certain pathological conditions may exacerbate oxidative damage to mitochondria, due to the uncoupling between mitochondrial NADPH generation and the NADH-dependent generation of oxidative stress from the electron transport chain.

Seemingly paradoxically, increasing evidence has suggested that NADPH could also significantly contribute to generation of oxidative stress through the activity of NADPH oxidase. NADPH oxidase is an enzyme that catalyzes the generation of superoxide from oxygen and NADPH. Increasing evidence has indicated that NADPH oxidase activity is present not only in phagocytes, but also in various tissues and cell types (26, 288). Seven members of NOX family of NADPH oxidase, including phagocyte NADPH oxidase itself (NOX2/gp91(phox)) and six homologs of the cytochrome subunit of the phagocyte NADPH oxidase (*i.e.*, NOX1, NOX3, NOX4, NOX5, DUOX1, and DUOX2) have been found (26). These enzymes share the capacity to transport electrons across the plasma membrane, leading to superoxide generation, which could be mediated by such factors as small guanosine triphosphatase Rac, protein kinase C, and  $Ca^{2+}$  (26, 124, 280, 288). There are significant tissue-dependent differences in the distribution of the various members of the NOX family (26, 101, 123).

Due to the pivotal roles of ROS in redox-based regulation of various biological functions (263), it is not surprising that NADPH oxidase appears to play important roles in not only host defense, but also a large variety of biological processes, including redox signaling (86), regulation of gene expression and cell differentiation, and post-translational modifications of proteins (26, 123). Of particular interest, many studies have indicated key roles of the NADPH oxidase-generated ROS in a variety of diseases, such as brain ischemia (26, 154, 266, 303), diabetic nephropathy (67), and cardiac hypertrophy (211).

It was found that NOX4 is preferentially localized to the nucleus of human umbilical vein endothelial cells, which appears to regulate gene expression by generating ROS in the nucleus (153). A recent study showed that ischemia induced NOX2 expression mainly at the nucleus of cardiomyocytes, which appears to mediate ischemia-induced apoptosis (196). It has also been found that the NADPH oxidase NOX2 is recruited to the early phagosomes of dendritic cells, which causes alkalization of the phagosomal lumen by generating ROS (251). These studies have indicated that NADPH oxidase is localized not only on plasma membranes, but also in such subcellular organelles as the nucleus. It is expected that future studies regarding the NADPH oxidases that are localized in subcellular

organelles would provide novel information about the roles of NADPH oxidase in biological functions and cell death. Figure 4 provides diagrammatic presentation of the pathways by which NAD and NADP affect antioxidation and ROS generation.


It is worthy to note that GSH/GSSG ratios may also affect the overall redox potential of cells due to the effects of GSH/GSSG on NAD/NADP metabolism: Decreased GSH/GSSG ratios may lead to decreased NADPH/NADP<sup>+</sup> ratios, due to the glutathione reductase-catalyzed regeneration of GSH from GSSG with consumption of NADPH; and the decreased NADPH/NADP<sup>+</sup> ratios may also affect NADH/NAD<sup>+</sup> ratios due to the modulating capacity of NADKs on the equilibrium between NADPH/NADP<sup>+</sup> ratios and NADH/NAD<sup>+</sup> ratios.

### C. NAD and NADP in calcium homeostasis

Mounting evidence has suggested that NAD<sup>+</sup> can mediate calcium homeostasis through multiple pathways: a) ADP-ribosyl cyclases can generate cyclic ADP-ribose from NAD<sup>+</sup>, which is a potent endogenous agonist of ryanodine receptor-mediated calcium channels (108); b) NAD<sup>+</sup> can also modulate calcium metabolism by promoting mono-ADP-ribosylation of P2X<sub>7</sub> receptors, which has been shown to increase P2X<sub>7</sub> receptor opening (17), thus leading to  $Ca^{2+}$  influx (216); c) ADP-ribose, a molecule that can be generated from NAD<sup>+</sup> by NAD glycohydrolases or PARPs/poly(ADP-ribose) glycohydrolase (PARG), can activate TRPM2 receptors leading to  $Ca^{2+}$  influx (98, 151); and d) Sir2 family proteins can generate O-acetyl-ADP-ribose that can directly bind to the cytoplasmic domain of the TRPM2 channels and produce TRPM2 channel opening, resulting in  $Ca^{2+}$  influx (107).

There is evidence suggesting that NADH can also directly modulate calcium homeostasis: Under hypoxic conditions, NADH can directly increase  $Ca^{2+}$  release from inositol 1,4,5-triphosphate (IP<sub>3</sub>)-gated  $Ca^{2+}$  channels on ER membranes of cerebellar Purkinje cells and nerve growth factor-differentiated PC12 cells (134). It has been further found that the GAPDH that is associated with IP<sub>3</sub>-gated calcium channels can locally generate NADH to promote the  $Ca^{2+}$  channel opening (228). NADH was also shown to inhibit ryanodine receptors of cardiac muscle, but not skeletal muscle (348, 349), which could be mediated by the NADH oxidase activity in cardiac sarcoplasmic reticulum (53).


NADP<sup>+</sup> is the major substrate for generation of NAADP that can mobilize intracellular  $Ca^{2+}$  stores (96). It has also been reported that NAADP regulates TRPM2 channels in T lympho-



**FIG. 4. Pathways by which NAD and NADP affect cellular antioxidation capacity and ROS generation.** NADH contributes to cellular reducing potential, and can also increase ROS generation by the electron transport chain (ETC) or by inducing iron release from ferritin. NADPH plays a key role in cellular antioxidation capacity by promoting glutathione reductase (GR)-mediated regeneration of GSH, reactivating catalase, and contributing to thioredoxin reductase (TrxR)-mediated generation of thioredoxin (TRx). NADPH can also be used by NADPH oxidase to generate superoxide.



**FIG. 5. Pathways by which NAD and NADP can affect calcium homeostasis.** ADP-ribosyl cyclases (ARCs), poly(ADP-ribose) polymerases (PARPs)/poly(ADP-ribose) glycohydrolase (PARG), and sirtuins use  $\text{NAD}^+$  as a substrate to generate several  $\text{Ca}^{2+}$ -mobilizing second messengers, including cyclic ADP-ribose (cADPR), ADP-ribose, and O-acetyl-ADP-ribose (O-acetyl-ADPR), which can activate TRPM2 receptors and ryanodine receptors (RyR).  $\text{NAD}^+$ -dependent mono(ADP-ribosyl)transferases (ARTs) can also affect calcium homeostasis by producing mono-ADP-ribosylation of  $\text{P2X}_7$  receptors (ADP-R- $\text{P2X}_7\text{R}$ ). NADH could modulate calcium homeostasis by affecting  $\text{IP}_3$ -gated calcium channels, mitochondrial permeability transition (MPT) and RyR. NAADP generated from NADP can also mobilize intracellular NAADP-dependent  $\text{Ca}^{2+}$  stores. NADPH may affect calcium homeostasis by its major effects on antioxidation and ROS generation, which can affect  $\text{Ca}^{2+}$  pumps and  $\text{Ca}^{2+}$  channels.



cytes (25). Increasing evidence has suggested that NAADP is one of the important endogenous factors mobilizing intracellular calcium stores (89, 159). It is of interest to note that  $\text{NADP}^+$  and  $\text{NAD}^+$ , which are essentially linked by NADKs, are the precursors for generating NAADP and cyclic ADP-ribose, respectively. Thus, it would be of interest to determine the roles of NADKs in the cyclic ADP-ribose and NAADP signaling pathways. Diagrammatic presentation of the pathways by which NAD and NADP affect calcium homeostasis is shown in Fig. 5.

*D. NAD and NADP in energy metabolism and mitochondrial functions*

NAD plays key roles in nearly all major aspects of energy metabolism (29, 328). NAD can mediate cytosolic energy metabolism through several pathways: NAD mediates glycolysis by acting as the co-factors for the glycolytic enzyme GAPDH; and NAD also modulates other important energy metabolism-related reactions in cytosol, such as the lactate dehydrogenase-catalyzed lactate—pyruvate conversions. In addition, cytosolic NADH can also affect mitochondrial oxidative phosphorylation due to the NADH shuttling from cytosol to mitochondria.

There are multiple mechanisms by which NAD can mediate mitochondrial energy metabolism: a) NADH is one of the major electron donors for the electron transport chain; b)  $\text{NAD}^+$  is the coenzyme for the three rate-limiting enzymes in TCA cycle (193); c) AIF is a NADH oxidase that plays an important role in the mitochondrial complex I activity (202); d) NADH could directly interact with and inhibit voltage-dependent anion channels, that is a component of MPT pores and controls the transport of small molecules across mitochondrial membranes (104); e) recent studies have demonstrated that  $\text{NAD}^+$ -dependent sirtuins can deacetylate the active lysine residues of acetyl-CoA synthetases, thus activating the enzymes, which

could mediate the conversion of free acetate to acetyl-CoA (114, 257, 273). In mammalian cells it appears that SIRT1 can deacetylate and activate acetyl-CoA synthetase 1 in cytosol (114), while SIRT3 can deacetylate and activate acetyl-CoA synthetase 2 in mitochondria (114, 257); and f) the NADH/ $\text{NAD}^+$  ratio is one of the modulators of MPT pore opening (352), which can significantly influence mitochondrial membrane potential. It has been suggested that maintenance of mitochondrial pyridine nucleotides in reduced redox state mediates the capacity of bcl-2 overexpression to block oxidative stress-induced MPT (132).

Studies suggest that under certain conditions the reducing equivalents of cytosolic NADH could be directly transferred to the oxygen in the mitochondria with the generation of electrochemical membrane potential, which is mediated by cytosolic cytochrome c and mitochondrial cytochrome oxidase (156, 189). In the model proposed by the researchers, the high energy electron from NADH is transferred to cytosolic cytochrome c by the NADH-cytochrome  $b_5$  oxido-reductase complex on external mitochondrial membrane; and the cytochrome c transfers the electron to mitochondrial complex IV (cytochrome oxidase) at the respiratory contact sites. Subsequently, the molecular oxygen is reduced with generation of electrochemical membrane potential. This process may occur at the early stage of apoptosis when significant amount of cytochrome c is released into cytosol, which may lead to additional energy generation for apoptosis. Moreover, this process may also occur under physiological conditions, since there may be constitutive release of cytochrome c from mitochondria to the cytosol (155). This process may not only contribute to removal of excessive cytosolic NADH, but also promote cell survival when the first three respiratory complexes are impaired.

Because transhydrogenase catalyzes the formation of ( $\text{NADPH} + \text{NAD}^+$ ) from ( $\text{NADP}^+ + \text{NADH}$ ) by utilizing the mitochondrial transmembrane electrochemical  $\text{H}^+$  gradient

(127, 246), mitochondrial NADPH generation could be linked with oxidative phosphorylation via transhydrogenase. It is possible that reversal of the transhydrogenase-catalyzed reactions may utilize NADPH to produce an increase in the proton gradient across the mitochondrial membranes. However, the relatively low free energy available for the reversal reaction suggests that the contribution of the reaction to the proton gradient is transient and insignificant (246). It was also hypothesized that IDPm may operate in reverse mode [*i.e.*, in the mode of generating isocitrate and NADP<sup>+</sup> from  $\alpha$ -ketoglutarate and NADPH, which may contribute to fine regulation of TCA cycle activity (253)]. This hypothesis has been supported by the studies demonstrating the reversal of the IDPm in liver (80) and heart (61), but not by a study applying a specific inhibitor of IDPm (253). Future studies are warranted to elucidate the relationships among transhydrogenase, mitochondrial NADPH generation, TCA cycle activity and mitochondrial oxidative phosphorylation. The potential significance of the studies has been highlighted by the findings suggesting that transhydrogenase deficiency could mediate the impairments of glucose-induced insulin release in C57BL/6J mice (284).

A recent study has indicated that IDPc mediates glucose-induced increases in pyruvate cycling and insulin secretion in primary rat islets (242), suggesting significant effects of IDPc on pyruvate-related energy metabolism. The finding that disruption of the NADH kinase POS5 in yeast dramatically increased the mitochondrial mutation rate (264) suggests a critical role of NADPH in protecting the integrity of mitochondrial DNA.

### E. Effects of NAD and NADP on gene expression

NAD may affect gene expression through several pathways. NADH mediates the activity of the corepressor carboxyl-terminal binding protein—a transcriptional factor important for cell cycle regulation, development, and transformation (342); and NADH also modulates the activities of Clock:BMAL1 and NPAS2:BMAL1 that are heterodimeric transcription factors controlling circadian clock-associated gene expression (245).

A number of studies have indicated important roles of PARP-1 in gene expression. For example, it has been found that both DNA topoisomerase II $\alpha$ -dependent, transient double-strand DNA breakage and subsequent PARP-1 activation is required for signal-dependent activation of gene expression by nuclear receptors and multiple other DNA-binding transcriptional factors (131, 175). Increasing evidence has suggested that PARP-1 could mediate gene expression through a number of mechanisms: first, PARP-1 can profoundly affect multiple transcriptional factors, including AP-1, AP-2, NF $\kappa$ B, p53, cAMP-responsive element-binding protein, Sry, and HIF1 (13, 111, 141, 170, 171, 186); second, PARP-1 binding on nucleosomes can reversibly modulate chromatin structure in a NAD<sup>+</sup>-dependent manner: PARP-1 binding on nucleosomes can promote the formation of transcriptionally repressed, compact chromatin structure, while PARP-1 autopoly(ADP-ribosylation) in the presence of NAD<sup>+</sup> produces dissociation of PARP-1 from chromatin, leading to the formation of transcriptionally active, decondensed chromatin structure (140, 141); third, PARP-1-produced poly(ADP-ribosylation) of histone H1 could also produce chromatin de-condensation (74, 232); fourth, PARP-1 can NAD<sup>+</sup>-dependently silence RNA polymerase II-dependent transcription (197, 217, 218); fifth, PARP-1 itself

can directly affect gene expression by binding the promoters of certain genes such as *iNOS* and *CXC ligand1* (8, 334); sixth, PARP-1 could affect gene expression by modulating DNA methylation (236, 335–337); and seventh, PARP-1-dependent NAD<sup>+</sup> consumption could affect gene expression by influencing the NAD<sup>+</sup>-dependent sirtuins that can modulate the activities of multiple transcriptional factors (200). The complexity of the mechanisms underlying the effects of PARP-1 on gene expression has been further indicated by the findings that PARP-1 can affect transcriptional factors through multiple mechanisms, such as direct protein–protein interactions (51, 118), modulations of the expression of transcriptional factors (111, 187), and poly(ADP-ribosylation) of transcriptional factors (170, 217).


Cumulative evidence has indicated increasingly extensive and important roles of PARP-1-mediated gene expression in various biological and pathological processes, such as inflammation and carcinogenesis (8, 111, 118, 141, 187). For example, a recent study has suggested that PARP-1 mediates nitric oxide-dependent negative feedback regulation of the expression of *iNOS* gene (334): PARP-1 appears to be a novel *trans*-activator of the *iNOS* promoter; and NO can inhibit *iNOS* expression by nitrosylating PARP-1. Figure 6 provides diagrammatic presentation of the pathways by which PARP-1 affects gene expression.

A number of studies have suggested that sirtuins can also mediate gene expression through multiple pathways: First, both yeast Sir2 and mammalian SIRT1 can produce histone hypoacetylation and gene repression by promoting the formation of heterochromatin—a tightly packed form of chromatin (200); second, SIRT1-produced deacetylation of multiple transcriptional factors, including p53 (179), FOXO transcriptional factors (209, 214), NF $\kappa$ B (317), p73 (75), and Tat (222), can mediate the transcriptional activities of these factors; third, SIRT7 is an activator of RNA polymerase I-mediated transcription (92); and fourth, SIRT1 has been found to inhibit RNA polymerase I-mediated transcription by deacetylating TAF<sub>768</sub> (212). A rapidly growing body of evidence has indicated that the effects of sirtuins on gene expression can significantly affect various biological processes, including aging, cell death, carcinogenesis, and stress resistance (200).

Since ROS can mediate gene expression by modulating intracellular redox state (262), it is conceivable that NADPH could affect gene expression by its profound effects on both cellular antioxidation and ROS generation. An interesting study reported that NOX4 is localized in the nucleus of human umbilical vein endothelial cells, which appears to regulate gene expression by generating superoxide (153). This finding provides a novel mechanism by which NADPH can affect gene expression: The NADPH oxidase in the cell nucleus may modulate gene expression by initiating redox signaling. It has also been found that the endothelial NADPH oxidase can be activated by angiogenic factors such as VEGF (289). The NADPH oxidase-generated ROS can activate various redox signaling pathways, resulting in angiogenesis-related gene expression, which may mediate postnatal angiogenesis *in vivo* (289).

### F. NAD and NADP in immunological functions

It has been found that CD38-produced cyclic ADP-ribose plays a critical role in inflammation and innate immune re-



**FIG. 6. Pathways by which PARP-1 affects gene expression.** PARP-1 can affect gene expression by influencing a number of transcriptional factors, or by direct binding to the promoters of certain genes. PARP-1 can also affect gene expression by producing chromatin de-condensation or compaction. The enzyme can further influence gene expression by silencing RNA polymerase II-dependent transcription, or by modulating DNA methylation. Moreover, PARP-1-dependent NAD<sup>+</sup> consumption could affect gene expression by influencing the NAD<sup>+</sup>-dependent sirtuins that can modulate the activities of several transcriptional factors.

sponses by mediating neutrophil chemotaxis to bacteria chemoattractants (225, 226). A recent study also indicated cyclic ADP-ribose as a second messenger mediating the lipopolysaccharide-induced proliferation of human peripheral blood mononuclear cells (43). Many studies have further demonstrated important roles of PARP-1 in inflammatory responses, due to its major effects on NFκB (296). It has also been reported that NADH can dose-dependently induce IL-6 release from human peripheral blood leukocytes (213). Recent studies have suggested that the ecto-ARTs can produce mono-ADP-ribosylation of P2X<sub>7</sub> receptors by consuming extracellular NAD<sup>+</sup>, leading to opening of P2X<sub>7</sub> receptors. The P2X<sub>7</sub> receptor opening can produce death of Treg cells—the cells that can inhibit the activation of other types of T cells (17).

PBEF was isolated as a presumptive cytokine that can enhance the maturation of B-cell precursors in the presence of stem cell factor and IL-7 (248). It has been demonstrated that PBEF is the same protein as Nampt—a key enzyme in the mammalian salvage pathway for NAD<sup>+</sup> synthesis (241), suggesting that a key NAD<sup>+</sup>-synthesizing enzyme can produce cytokine-like effects when acting extracellularly. It is of interest to further determine if the cytokine-like activity of PBEF might be accounted for by the nicotinamide mononucleotide-synthesizing capacity of Nampt (238).


The NADPH oxidase in phagocytes plays critical roles in innate immunity by generating microbicidal ROS (167). Increasing evidence has suggested that several other members of the Nox family of oxidases are also involved in host defense (167). Important roles of NADPH oxidase in the inflammation under several pathological conditions have been indicated by the findings that inhibition of NADPH oxidase can block inflammatory processes (157, 239). The interactions between NADPH oxidase and inducible NOS (iNOS) play key roles in inflamma-

tion-induced cytotoxicity: iNOS is a Ca<sup>2+</sup>-independent and transcriptionally regulated isoform of NOS. Activated iNOS can generate large toxic amount of NO in a sustained manner (109). The NADPH oxidase-generated superoxide can rapidly interact with the iNOS-generated NO to produce peroxynitrite that mediates the toxicity of NO by producing DNA damage, inhibiting mitochondrial respiration and activating PARPs (110, 125). Multiple studies have indicated that NADPH oxidase and iNOS can produce synergistic effects in inducing death of several types of cells (38, 169).

A recent study has demonstrated that the NADPH oxidase NOX2 is recruited to the early phagosomes of dendritic cells, which produces alkalinization of the phagosomal lumen by generating low levels of ROS (251). Through this process NOX2 confers dendritic cells the ability to function as specialized phagocytes for processing antigens rather than killing pathogens (251). It has also been found that the absence of one of the components of NADPH oxidase is causative to chronic granulomatous disease—an inherited immune deficiency disease (21). Diagrammatic presentation of the mechanisms by which NAD and NADP affect immunological functions is shown in Fig. 7.

### G. NAD and NADP in vascular activity

Angiotensin II plays key roles in regulating vascular activity, which produces multiple vascular effects through NADPH oxidase-derived ROS (120). Recent studies have suggested that NADH/NAD<sup>+</sup> ratios and NADPH oxidase play critical roles in two of the important models for the oxygen sensing in hypoxic pulmonary vasoconstriction (304). There are also studies suggesting that NADPH mediates the differential responses of pulmonary artery and coronary artery to hypoxia (307): The hy-



**FIG. 7. Pathways by which NAD and NADP could affect immunological functions.** NAD<sup>+</sup>-dependent poly (ADP-ribose) polymerase-1 (PARP-1) plays a significant role in immunological functions due to its close relationships with NFκB. NAD<sup>+</sup>-dependent generation of cyclic ADP-ribose (cADPR) by CD38 can also mediate the cell signaling in immune cells. Ecto-mono-ADP-ribosyl transferases (ARTs) can induce Treg cell death by using NAD<sup>+</sup> to produce mono-ADP-ribosylation of P2X<sub>7</sub> receptors (ADP-R-P2X<sub>7</sub>R). NADPH oxidase is responsible for the ROS burst in phagocytes. NADH may also affect the immune system by inducing cytokine release from peripheral leukocytes.

poxia-induced pulmonary artery contraction could be mediated by a mechanism associated with a decrease in the basal levels of NADPH oxidase-generated peroxide; while hypoxia-induced coronary artery dilation could be mediated by a decrease in the basal levels of NADPH.

Mounting evidence has suggested that NAD and NADP metabolism also plays significant roles in vascular damage under various pathological conditions. For example, a PARP inhibitor was found to decrease cardiopulmonary bypass-induced mesenteric vascular dysfunction by improving hemodynamics, decreasing neutrophil adhesion, and restoring nitric oxide production (12); and the C242T CYBA polymorphism of NADPH oxidase was found to be associated with essential hypertension (205).

#### H. NAD and NADP in carcinogenesis and cancer treatment

Selective inhibition of NAD<sup>+</sup> synthesis has been shown to induce apoptosis of tumor cells (117). Because PARP-1 plays critical roles in regulating DNA repair, genomic stability, and cell cycle progression (296), many studies have been conducted to determine the roles of PARP-1 in carcinogenesis (103). It has been found that PARP inhibitors can restore the sensitivity of resistant tumors to topoisomerase I inhibitors or methylating agents (103). Because telomerases and telomere play significant roles in carcinogenesis (112), NAD<sup>+</sup>-dependent tankyrases—the enzymes that regulate telomerase activity (259, 260)—may affect carcinogenesis by influencing telomere.

Increasing evidence has indicated that sirtuins may be involved in carcinogenesis and cancer treatment. A recent study suggests that cancer cells, but not noncancerous cells, may require SIRT1 for survival (93); decreased levels of SIRT1 by RNA silencing selectively induced apoptosis and/or growth arrest in human epithelial cells, while the RNA silencing did not affect normal human epithelial cells. Another recent study also indicated that SIRT1 inhibition by tumor suppressor HIC1 in

human MCF-7 cancer cells mediates DNA damage-induced apoptosis by both producing p53 acetylation and suppressing the antiapoptotic factor bcl-2 (52).

It has been indicated that the thioredoxin system, that consists of NADPH, thioredoxin, and thioredoxin reductase, plays an important role in carcinogenesis and invasive phenotype of cancer (16). Because NAD and NADP can profoundly affect cell death and various biological processes including gene expression and signal transduction, future studies may further elucidate important roles of NAD and NADP in carcinogenesis and cancer treatment.

#### I. NAD and NADP in aging

Accumulating evidence has suggested that NAD could be a crucial factor in the aging process by regulating sirtuins, PARP-1, tankyrases, and oxidative stress. It has been indicated that Sir2 is a key enzyme mediating the life span of yeast and *C. elegans* (35). The study of Lin *et al.* suggested that calorie restriction could modulate Sir2 activity, thus extending the life span of yeast by decreasing NADH levels (173). However, Anderson *et al.* (10) have suggested an intriguing alternative mechanism by which calorie restriction and Sir2 mediate the lifespan of yeast: *PNC1* (pyrazinamidase/nicotinamidase 1) encodes an enzyme that converts nicotinamide to nicotinic acid, which can lead to Sir2 activation by depleting the Sir2 inhibitor nicotinamide. It was shown that *PNC1* is a novel longevity gene that is both necessary and sufficient for the lifespan extension by calorie restriction, which appears to be mediated by *PNC1*-dependent activation of Sir2. It has also been found that deficiency of SIRT6, a human homolog of Sir2, produces aging-like phenotype and genomic instability in mice (208). A recent study has suggested that the gene encoding the key NAD<sup>+</sup>-synthesizing enzyme Nampt is a novel longevity gene, which can significantly extend the replicative lifespan of human cells by increasing SIRT1 activity, leading to inhibition of age-dependent p53 expression and increased p53 degradation (293).

Telomere and telomerases have been indicated as mediators of cellular aging (36).  $NAD^+$  may also affect the aging processes through  $NAD^+$ -dependent tankyrases, because tankyrases mediate telomerase activity (270). It has also been reported that PARP activities of mononuclear blood cells are strongly correlated with the longevity of thirteen mammalian species, which may be accounted for by the DNA repair function of PARP-1 (45, 106). A role of PARP-1 in aging has been further suggested by the finding that PARP-1 inhibits the catalytic activities of the protein of Werner syndrome, a human disease of premature aging (298, 299). Moreover, due to the significant roles of mitochondrial impairments in the aging processes (47, 265), it is conceivable that NAD may further influence aging by its profound effects on mitochondrial activities.

Due to the important role of oxidative stress in aging (113, 272, 321), it is conceivable that NADPH may play significant roles in aging due to the effects of NADPH on both antioxidation and ROS generation. It has been reported that IDPc regulates replicative senescence (139). There are also increased levels of glycated IDP in IMR-90 cells and rat kidney during normal aging (138). The glycation-mediated damage to IDP may increase oxidative stress and contribute to aging-related alterations (138).

Seemingly paradoxically, the patients of glucose-6-phosphate dehydrogenase deficiency could have longer lifespan (256), which might be accounted for by the decreased NADPH oxidase-dependent ROS generation resulting from decreased NADPH generation. Future studies are needed to further elucidate the roles of NADPH in both chronological and replicative senescence, and to search for the potential strategies to increase longevity by manipulating NADPH me-


tabolism. Figure 8 provides diagrammatic presentation of the pathways by which NAD and NADP could affect the aging process.

#### IV. NAD AND NADP IN CELL DEATH

##### A. PARP-1 and NAD in cell death

Oxidative stress has been indicated as a key mediator of ischemic brain damage (49, 50), Parkinson's disease (PD) (24, 308, 321), Alzheimer's disease (AD) (137, 199, 204, 319, 346) and many other diseases (113). Excessive PARP-1 activation appears to mediate cell death induced by oxidative stress under many conditions (87, 341). There has also been compelling evidence indicating that PARP-1 activation plays a key role in ischemic brain injury: both pharmacological and genetic inhibition of PARP-1 can profoundly decrease infarct formation in animal models of brain ischemia (87, 88), and increased PARP activities have been found in animal models of cerebral ischemia (88, 283) and in human brains after cardiac arrest (176).

Evidence suggests that PARP-1 may also mediate the neuronal injury in PD and AD: PARP-1 activation has been shown to mediate the neuronal death induced by MPTP, a model toxin for PD, both *in vitro* (66, 185) and *in vivo* (126, 184, 234). Increased nuclear PARP activity has also been found in the brains of AD patients (48, 126). A recent study reported that PARP-1 activation mediates the  $\beta$ -amyloid-induced neuronal death, which is an *in vitro* model of AD (91, 119). Cumulative evidence has further indicated that PARP-1 activation is an important pathological factor in traumatic brain injury (158), hy-



**FIG. 8. Potential pathways by which NAD and NADP can affect the aging process.**  $NAD^+$  could affect aging process through the  $NAD^+$ -dependent enzymes sirtuins, poly(ADP-ribose) polymerase-1 (PARP-1), and tankyrases. NADPH may affect aging by its major effects on cellular antioxidation capacity and ROS generation. NADH may affect aging by its effects on mitochondrial activities, ROS generation, and cellular reducing potential. Nicotinamide phosphoribosyltransferase (Nampt) may slow aging by promoting  $NAD^+$  generation from nicotinamide.

poglycemic brain injury (277), diabetes (229), and shock and inflammation (279, 296). PARP-1 has become a valuable therapeutic target for multiple diseases (230, 279, 296).

Our studies have provided direct evidence demonstrating that NAD<sup>+</sup> depletion is a key step mediating PARP-1-induced cell death (5, 326). Several studies have also indicated that MPT (5) and apoptosis-inducing factor (AIF) translocation (332) link NAD<sup>+</sup> depletion to cell death. Our studies have further suggested that NAD<sup>+</sup> depletion could induce mitochondrial impairments by producing glycolytic inhibition (326), which would reduce pyruvate supply to TCA cycle (325). This suggestion has been supported by the findings of us and other researchers, which show that pyruvate treatment after PARP-1 activation can profoundly decrease PARP-1-induced impairments of energy metabolism and cell death in cell cultures, brain slices, and animal models of diseases (278, 325, 338).


Several recent studies have suggested novel mechanisms underlying PARP-1 cytotoxicity. It was reported that SIRT1 is a key link between NAD<sup>+</sup> depletion and cell death (231). A latest study has further indicated interactions between PARP-1 and SIRT1: SIRT1 deficiency produces significant increases in PARP-1 activity, leading to AIF-mediated cell death (149). Several studies have also indicated that the ADP-ribose generated by PARP-1/PARG can produce TRPM2 opening, leading to increased intracellular calcium concentrations and cell death (90, 91, 314). However, two recent studies suggested that PAR, instead ADP-ribose monomers, mediates PARP-1-induced AIF translocation and cell death (11, 333).

Increasing evidence has indicated multiple protein kinases, including extracellular signal-regulated kinases (ERKs) and c-Jun N-terminal kinases (JNKs), could contribute to PARP-1-mediated cell death (59, 136, 310, 343). Xu *et al.* reported that JNK, particularly JNK1, is required for PARP-1-induced mitochondrial impairments and subsequent cell death (6, 310). A recent study has further indicated that JNK1 could activate PARP-1 by directly phosphorylating the enzyme (343). It has also been indi-

cated that ERK1/2 induces PARP-1 activation by directly phosphorylating the enzyme (136). The latest study by Cohen—Armon *et al.* reported that phosphorylated ERK2 can induce DNA damage-independent PARP-1 activation by directly interacting with the enzyme (59). Figure 9 provides diagrammatic presentation of the mechanisms for PARP-1-mediated cell death.

There are several possibilities underlying the seeming diversity of the mechanisms underlying PARP-1 toxicity. First, while the reported mechanisms for PARP-1 toxicity seem diverse, future studies may expose a common pathway linking these mechanisms. Second, multiple factors may form a detrimental network that leads to PARP-1-initiated cell death, thus inhibition of any one of the major components of the network may block PARP-1 toxicity. Third, there may be differential PARP-1-mediated cell death cascades that are selectively activated depending on cell types and intensities of insults. Fourth, we have demonstrated that inclusion of such nutritional factors as pyruvate or  $\alpha$ -ketoglutarate can profoundly affect PARP-1 toxicity (325, 338). Thus, the differential nutritional compositions of the experimental media in different studies may contribute to the variability of the experimental outcomes (327).

Recent studies have suggested that other PARPs could also mediate cell injury. It has been found that overexpression of tankyrase 2 can produce rapid cell death (182). Tankyrase 1 has also been shown to interact with both Mcl-1L (myeloid cell leukemia-1 long) and Mcl-1S (myeloid cell leukemia-1 short) proteins, which are anti-apoptotic and pro-apoptotic bcl-2 family proteins, respectively (22). Tankyrase 1 overexpression can antagonize both Mcl-1L-mediated cell survival and Mcl-1S-induced cell death (22). Intriguingly, PARP-2 was detrimental in focal brain ischemia, while it was beneficial in a model of global ischemia (181). A recent study has further suggested that PARP-2 mediates the survival of CD4<sup>+</sup>CD8<sup>+</sup> double-positive T cells during thymopoiesis (316). It is warranted to further determine the interactions among PARPs under both physiological and pathological



**FIG. 9. Mechanisms of poly(ADP-ribose) polymerase-1 (PARP-1) cytotoxicity.** Excessive PARP-1 activation triggered by single-strand DNA (ssDNA) can induce NAD<sup>+</sup> depletion, leading to glycolytic inhibition and SIRT1 inhibition, which could lead to mitochondrial permeability transition, resulting in apoptosis-inducing factor (AIF) translocation, ATP depletion, and subsequent cell death. ADP-ribose can be generated by poly(ADP-ribose) glycohydrolase (PARG) from poly(ADP-ribose) (PAR), which can induce TRPM2 receptor opening, leading to increased intracellular calcium concentration and cell death. PARP-1 activation can also activate c-Jun N-terminal kinase (JNK) that can produce mitochondrial impairments and cell death.

conditions, and to elucidate the relationships between NAD and PARPs in cell survival.

*B. PARG in cell death*

PARG mediates PAR catabolism in cells (77), which degrades PAR into ADP-ribose (243). PARG is an endo-exoglycosidase that exists in low abundance in cells, which appears to play significant roles in regulation of gene expression, cell cycle, and cell differentiation (84, 219, 287). A recent study reported that in *Drosophila* PARG mediates Sir2-dependent silencing and chromatin structure (285).

Cumulative evidence has implicated that PARG inhibition may prevent PARP-1-mediated cell death by several mechanisms (323, 324): First, PARP-1 can auto-poly(ADP-ribosyl)ate itself, leading to PARP-1 auto-inhibition (74). Therefore, PARG inhibition prevents removal of PAR from PARP-1, thus indirectly inhibiting PARP-1 activation. Second, PARG inhibition could block the rapid PAR turnover, thus preventing NAD<sup>+</sup> depletion. Third, Ca<sup>2+</sup>-Mg<sup>2+</sup>-dependent endonucleases (CME) mediate DNA fragmentation in certain apoptotic cascades (39). It has been found that CME can be poly(ADP-ribosyl)ated, thus being inhibited under physiological conditions (39, 311). Thus, PARG inhibition can prevent removal of PAR from CME, leading to sustained CME inhibition. Fourth, several studies have suggested that PARP-1/PARG activities can generate ADP-ribose by hydrolyzing PAR, leading to activation of TRPM2 receptors and consequent cell death (90, 91, 314). Therefore, PARG inhibition could also decrease cell death by blocking ADP-ribose generation from PAR. Figure 10 provides diagrammatic presentation of the potential mechanisms underlying the protective effects of PARG inhibition.

All of the *in vitro* and *in vivo* studies using various structurally different PARG inhibitors, including GPI 16552 [*N*-bis-(3-phenylpropyl)9-oxo-fluorene-2,7-diamide] (178), GPI 18214 (100), gal-

lotannin, and nobotanin B (23, 121, 142, 323, 324), have supported the hypothesis that PARG may be a new target for decreasing oxidative cell death (71, 328): The PARG inhibitor gal- lotannin and nobotanin B can decrease cell death induced by various PARP activators *in vitro* (23, 121, 142, 323, 324); our latest study has shown that intranasal gal- lotannin administration can inhibit PARG and profoundly decrease ischemic brain injury and AIF translocation *in vivo* (305); the PARG inhibitor GPI 16552 can also markedly reduce ischemic brain injury (178) and spinal cord injury (72); and it was reported that the PARG inhibitor GPI 18214 is beneficial for septic shock-like syndrome (100) and inflammatory bowel disease (73).


In the cell culture studies in which PARG activity was decreased by PARG antisense oligonucleotides or PARG small interference RNA, it was also found that PARG inhibition is cytoprotective: Decreases of PARG levels by PARG antisense oligonucleotides (46) or RNA silencing (37) led to reduced PARP-1-mediated cell death. Of particular interest, a recent study using a cell culture model that has increased PARG activity has further suggested that PARG inhibition could be protective: The increased PARG activity was found to accelerate NAD<sup>+</sup> depletion and increase cell death (97).

However, the studies using PARG knockout mice have generated variable results: the mice that have genetic deletion of the 110 kDa PARG isoform have significantly decreased spinal cord injury (72) and ischemic damage of intestine (70) and kidney (227) compared with wild-type mice. However, there are also studies suggesting that genetic deletion of PARG leads to detrimental effects (11, 68). Since increasing evidence has indicated that PARG significantly affects gene expression and other biological properties (84, 219, 287) and that the *PARG* gene is closely associated with *inner mitochondrial membrane translocase 23 (TIM23)* gene (198), attention should be paid to the potential genetic alterations in the PARG knockout mice. Indeed, it has been reported that in PARG knockout mice, there are marked changes in the gene expression of cyclooxygenase 2 and heat shock protein 70 (68)—two important proteins in cellular functions and cell survival.

Based on the considerations of the available observations about PARG in cell death, it is tempting to conclude that partial PARG inhibition can be cytoprotective, whereas complete PARG inhibition can be detrimental. Future studies using conditional PARG knockout mice or more selective PARG inhibitors are warranted to further elucidate the role of PARG in cell death.

*C. NAD in apoptosis*

In contrast to the extensiveness of the studies on PARP-1, a mediator of programmed necrosis (350, 351), there have been only insufficient number of studies on the roles of NAD in apoptosis. Several studies have suggested that NAD may be involved in apoptosis: it was reported that selective inhibitors of NAD<sup>+</sup> synthesis can induce apoptosis (117), and that NADH/NADPH depletion is an early event in apoptosis (99). NAD may affect apoptosis through several potential mechanisms: First, NAD mediates cellular energy metabolism that is a critical factor determining cell death modes; second, the NADH/NAD<sup>+</sup> ratio is a major index of cellular reducing power that affects MPT—a mediator of apoptosis under many conditions (352); third, NAD<sup>+</sup> levels mediate the activity of caspase-dependent en-



**FIG. 10. Potential mechanisms by which PARG inhibition may decrease PARP-1-mediated cell death.** PARG inhibition may be cytoprotective by prolonging auto-poly(ADP-ribosylation)-produced PARP-1 inhibition, by slowing poly(ADP-ribose) (PAR) turnover, by blocking ADP-ribose generation, or by maintaining poly(ADP-ribosylation)-produced inhibition of Ca<sup>2+</sup>-Mg<sup>2+</sup>-dependent endonucleases (CME).

donuclease DFF40—an executioner of DNA fragmentation in certain apoptotic cascades (128); and fourth, NAD<sup>+</sup>-dependent sirtuins may mediate apoptosis (317). Future studies on this topic are critical for our comprehensive understanding about the roles of NAD in cell death.

#### D. NAD in axonal degeneration

Axonal degeneration is one of the major pathological changes in many neurodegenerative diseases (60). The Wallerian degeneration slow [Wld(S)] mouse model has been valuable for investigating the mechanisms underlying axonal degeneration (60). The mutation of Wld(S) mice leads to overexpression of a chimeric protein—Wld(S) protein consisting of the key NAD<sup>+</sup>-synthesizing enzyme NMNAT-1 and the ubiquitin assembly protein Ufd2a, which can lead to delay of injury-induced axonal degeneration. Recent studies have suggested that the NMNAT-1 in the Wld(S) protein could mediate the protective effects of the Wallerian mutation (14, 302): one study suggested that the increased NMNAT-1 expression produces its effects by affecting SIRT1, a member of sirtuins (14). However, another study reported that NMNAT-1 may affect axonal degeneration by preventing NAD<sup>+</sup> loss in degenerating axons (302). A later study has further suggested that NMNAT-1 activity is required for the protective effects of Wld(S) protein (129). However, there are also studies suggesting that NMNAT-1 itself may be insufficient to account for the protective effects of the Wld(S) protein (62, 340).

#### E. AIF and GAPDH in cell death

In addition to PARP-1, the other two NAD-dependent proteins—AIF (202) and GAPDH (58, 115)—are also important mediators of cell death. GAPDH has been established as a mediator of apoptosis under many conditions: GAPDH binds Siah which is then translocated into nucleus to mediate apoptosis (58, 115, 116, 252).

AIF is a NADH oxidase, which appears to be both an important pro-death factor and an important pro-survival factor (76, 174, 202). Translocation of AIF from mitochondria to the nucleus has been indicated as mediators of caspase-independent apoptosis (202) and PARP-1 cytotoxicity (332). However, AIF also plays a significant role in mitochondrial complex I activity (290). Genetic deletion of AIF has been shown to produce skeleton muscle atrophy, dilated cardiomyopathy, and neurodegeneration (202). There has been evidence indicating that prevention of NAD<sup>+</sup> depletion can block PARP-1-mediated nuclear translocation of AIF (5). This finding, together with the fact that AIF is a NADH oxidase, suggests that NAD could be an important regulator of AIF. Our latest study has shown that aurointricarboxylic acid—a CME inhibitor—can nearly abolish DNA alkylating agent-induced nuclear condensation in astrocytes, despite nuclear translocation of AIF (unpublished finding). This result suggests that, at least under certain conditions, nuclear AIF translocation itself may be insufficient to induce chromatin condensation.

#### F. NADP in cell death

There are studies suggesting the protective roles of IDPm in defending against cell apoptosis induced by various insults:

IDPm is involved in cell defense against cadmium-induced apoptosis (139); administration with oxalomalate—a competitive inhibitor of IDPm—leads to increased ionizing radiation-induced apoptosis in mice (161); and modulation of IDPm activity in HEK293 cells also significantly affects high glucose-induced apoptosis (267).

Of particular interest, a large number of studies have indicated that NADPH oxidase plays a key role in cell death under both *in vitro* and *in vivo* conditions (2). For example, it was reported that the NADPH oxidase activation in astrocytes mediates  $\beta$ -amyloid-induced neuronal death (1); NADPH oxidase also plays a key role in the ROS generation in the neurons that are exposed to oxygen—glucose deprivation—an *in vitro* model for brain ischemia (3); and genetic or pharmacological inhibition of NADPH oxidase is protective against ischemic brain injury (300). A recent study also reported that ischemia induced NOX2 expression mainly at the nucleus of cardiomyocytes, which appears to mediate ischemia-induced apoptosis (196). Due to the critical roles of oxidative stress in cell death (247), it is expected that there would be an increasing number of studies indicating significant roles of NADPH in cell death.

## V. THERAPEUTIC POTENTIAL OF NAD AND NADP

### A. Therapeutic potential of NAD<sup>+</sup> precursors

A number of *in vitro* studies have shown that nicotinamide can produce cytoprotective effects against various insults, including oxidative stress and oxygen—glucose deprivation (57, 168). Nicotinamide administration has also been shown to decrease tissue injury in several animal models of diseases, including cerebral ischemia (19, 20, 203, 312), spinal cord injury (40), PD (210), and multiple sclerosis (133). Nicotinamide could produce cytoprotective effects by multiple mechanisms, including inhibition of PARP-1 (145, 296), restoration of NAD<sup>+</sup> levels (145, 312), activation of Akt1 (56), and blockage of mitochondrial permeability transition and mitochondrial depolarization (55, 168). However, since it is also an inhibitor of sirtuins (18), nicotinamide may produce detrimental effects on cell survival and longevity.

A recent study reported that nicotinamide riboside—a newly discovered NAD<sup>+</sup> precursor in eukaryotes—can promote Sir2-dependent gene silencing and markedly extend the replicative lifespan of yeast without calorie restriction (28). It was further found that the beneficial effects of nicotinamide riboside are mediated by the capacity of nicotinamide riboside to increase NAD<sup>+</sup> synthesis (28). This study suggests a novel approach to increase NAD<sup>+</sup> synthesis and extend life span of cells.

### B. Therapeutic potential of NAD<sup>+</sup>

The recent studies by our research group have provided the first evidence indicating that treatment with NAD<sup>+</sup> can abolish PARP-1-induced astrocyte death (5, 326, 327, 345). It was also shown that NAD<sup>+</sup> treatment can decrease PARP-1-induced myocyte death (231). These results raise the possibility that NAD<sup>+</sup> may be used *in vivo* to decrease PARP-1-mediated tis-



sue injury. This possibility has been further enhanced by the observations that NAD<sup>+</sup> levels are significantly decreased by a PARP-mediated mechanism in the brains that underwent ischemia/reperfusion (77).

Based on this information, we have used a rat model of transient focal ischemia to test our hypothesis that administration with NAD<sup>+</sup> can reduce ischemic brain damage (277): we found that intranasal delivery of NAD<sup>+</sup> at 2 h after ischemic onset decreased infarct formation by up to 87% and significantly attenuated ischemia/reperfusion-induced neurological deficits (Fig. 11). In contrast, intranasal delivery of nicotinamide at the same dose did not reduce ischemic brain damage. These results provide the first *in vivo* evidence that NAD<sup>+</sup> metabolism is a new target for treating cerebral ischemia, and that NAD<sup>+</sup> administration may be a novel strategy for decreasing ischemic brain injury.

There is evidence implicating that NAD<sup>+</sup> administration may decrease brain injury in not only cerebral ischemia, but also multiple other diseases (331): pathological roles of PARP-1 have also been implicated in many diseases such as diabetes, PD, and AD (329). Since NAD<sup>+</sup> treatment provides the most profound protection against PARP-1-mediated cell injury in cell culture studies, NAD<sup>+</sup> administration might reduce the cell injury in these diseases at least partially by decreasing PARP-1 toxicity. Our latest study has suggested that intranasal NAD<sup>+</sup> administration might also decrease traumatic brain injury (330), which supports our proposal that NAD<sup>+</sup> may be used to treat multiple diseases (331).

NAD<sup>+</sup> may have distinctive merits as a cytoprotective agent. *In vitro* studies have shown that NAD<sup>+</sup> can produce greatest protective effects against PARP-1 cytotoxicity (5, 326), and NAD<sup>+</sup> is also protective even when applied at 3–4 h after PARP-1 activation, suggesting that NAD<sup>+</sup> administration may have a long window of opportunity in decreasing tissue injury. In addition, NAD<sup>+</sup> may further decrease cell death by other pathways, such as enhancing sirtuin activities and energy metabolism.

### C. Therapeutic potential of NADH


Several studies have reported beneficial effects of NADH administration in treating PD (34, 152), which may be partially explained by the capacity of NADH to increase bioavailability of plasma levodopa. NADH administration can also improve cognitive functions (78), suggesting the potential of NADH for treating AD patients. Our recent studies have provided direct evidence that NADH treatment can significantly decrease PARP-1-mediated cell death (345), which further raises the possibility that NADH may be used to treat PARP-1-associated illnesses.

### FIG. 11. Intranasal NAD<sup>+</sup> administration can profoundly decrease ischemic brain injury in a rat model of brain ischemia.

The infarct size of the rats that underwent ischemia/reperfusion (I/R) (upper panel) was significantly larger than that of the rats that underwent I/R and received intranasal administration with NAD<sup>+</sup> (lower panel). As shown in the photographs, the white-colored tissues are the infarcted tissues.

I/R

I/R + NAD<sup>+</sup>



### D. Therapeutic potential of modulations of NADPH oxidase

Because NADPH can act as either a ‘good guy’ or a ‘bad guy’ in cellular antioxidation systems, it could be important for cell survival to maintain NADPH as a ‘good guy’. Particularly since NADPH oxidase can play critical pathological roles in multiple diseases, it is of importance to modulate NADPH-related properties to decrease the detrimental effects of NADPH in the diseases. There could be several strategies for mitigating NADPH oxidase activity: First, to directly inhibit NADPH oxidase by using NADPH oxidase inhibitors; second, to indirectly inhibit NADPH oxidase by manipulating the intracellular modulators of the enzyme, such as the small guanine triphosphatase Rac and protein kinase C (26, 124, 288); third, to inhibit excessive generation of NADPH by modulating the multiple NADPH-generating reactions; and fourth, to maintain the activities of NADPH-consuming enzymes such as glutathione reductase so as to ensure efficient NADPH flux through these pathways, thus preventing excessive NADPH supply to NADPH oxidase.

## VI. CONCLUSIONS

Based on the above discussion, it appears that the classical paradigm regarding the biological functions of NAD and NADP is too narrow to generalize the growing functions of these molecules. It is tempting to propose that a novel paradigm about the biological functions of NAD and NADP may be emerging: NAD and NADP could be the fundamental common mediators of nearly all major biological activities, including mitochondrial function, energy metabolism, calcium homeostasis, antioxidation/generation of oxidative stress, gene expression, immunological functions, aging, and cell death. Selected from the information reviewed above regarding the biological functions of NAD and NADP, the following pieces of information could serve as the highlights for supporting the emerging new paradigm: In addition to the established pivotal roles of NAD in mitochondrial functions and energy metabolism, cyclic ADP-ribose and multiple other molecules that are generated from NAD and NADP could be the essential regulators of calcium homeostasis. NAD and NADP also play key roles in both antioxidation and ROS generation: NADPH is an essential component in cellular antioxidation systems; and the NADH-dependent ROS generation from the electron transport chain and the ROS generation by NADPH oxidase are two key mechanisms of ROS generation. NAD and NADP appear to mediate cell death by modulating several key factors in cell death,


such as MPT, energy state, and the activities of the NAD- and NADP-dependent enzymes, including PARP-1, GAPDH, AIF, and NADPH oxidase. Furthermore, in addition to the major effects of NAD and NADP on several factors that could play key roles in senescence, including oxidative stress, mitochondrial functions, and telomere metabolism, NAD-dependent sirtuins have emerged as a mediator of the aging process; and the genes encoding the enzymes involving in NAD<sup>+</sup> metabolism, including *PNC1* (10) and the gene encoding Nampt (293), appear to be novel longevity genes.

Growing evidence has also suggested a novel paradigm for the metabolism of NAD and NADP, which consists of the following major concepts: first, NAD and NADP can be metabolized by many enzymes to generate multiple bioactive molecules, such as cyclic ADP-ribose, ADP-ribose, poly(ADP-ribose), NAADP, and O-acetyl-ADP-ribose; second, there are NAD<sup>+</sup>-synthesizing and NAD<sup>+</sup>-catabolizing enzymes in not only the nucleus, but also in other subcellular organelles including the Golgi complex and mitochondria; third, extracellular NAD<sup>+</sup> can be metabolized by such ecto-enzymes as ecto-ARTs or CD38 to produce biological effects (33); and NAD<sup>+</sup>-synthesizing processes might also be catalyzed extracellularly by Nampt (238); fourth, NAD can be transported across the plasma membranes of certain cell types; fifth, there are close interactions among the key enzymes in NAD and NADP metabolism, such as the interactions between NMNAT-1 and

PARP-1; and sixth, at least in yeast there are such novel metabolic pathways of NAD and NADP as the pathways mediated by NADH kinase and acetaldehyde dehydrogenase. Figure 12 provides a diagrammatic overview about the metabolism and the biological functions of NAD and NADP.

As proposed in previous articles (328, 329), NAD, together with ATP and Ca<sup>2+</sup>, may be the most fundamental components in life which mediate nearly all of the key biological processes (328, 329). The close interactions among these components may constitute a 'Central Regulatory Network' in life (329). The highly extensive functions of these seemingly simple molecules and ions may be important factors underlying the exquisite regulation and profound potential of life.

Much theoretical investigation is still needed to improve the 'Central Regulatory Network Hypothesis of Life.' The interactions between ROS and the 'Central Regulatory Network' could be of particular importance. As discussed in the articles about 'deleterious network hypothesis' of neurodegenerative diseases, aging, and cell death (318–322), there are close interactions among ROS, calcium homeostasis, and energy metabolism. Profound interactions between ROS and NAD/NADP have also been generalized in the current review. Because ROS plays important roles in many biological functions, it is proposed that ROS is an important factor that closely interacts with all of the three major components of the 'Central Regulatory Network.' Certain environmental and genetic factors may cause excessive



**FIG. 12. Metabolism and biological activities of NAD and NADP.** NAD<sup>+</sup> can be generated from the salvage pathway using nicotinic acid mononucleotide (NaMN) or nicotinamide mononucleotide (NMN) as precursors, or from the *de novo* pathway using quinolinic acid (QA) as the precursor. Through NAD<sup>+</sup>-dependent dehydrogenases, poly(ADP-ribose) polymerases (PARPs), sirtuins, ADP-ribosyl cyclases (ARCs), and mono(ADP-ribosyl)transferases (ARTs), NAD<sup>+</sup> can significantly affect mitochondrial function, energy metabolism, calcium homeostasis, gene expression, aging, and cell death. NADH can be generated from NAD<sup>+</sup> by NAD-dependent dehydrogenases, which is used by the electron transport chain (ETC) or NADH oxidases. NADH can significantly affect mitochondrial function, energy metabolism, oxidative stress, calcium homeostasis, and gene expression. NADP<sup>+</sup> can be generated from NAD<sup>+</sup> by NAD<sup>+</sup> kinases (NADK), which can be used for NADPH generation through glucose-6-phosphate dehydrogenase (G6PDH), 6-glyconate phosphate dehydrogenase (6GPDH), NADP<sup>+</sup>-dependent isocitrate dehydrogenases (IDPs), NADP<sup>+</sup>-dependent malic enzymes (MEPs), and transhydrogenase (TH). NADPH can be used by glutathione reductase, NADPH oxidase, and other NADPH-dependent enzymes to mediate antioxidation, ROS generation, and reductive synthesis. NADP<sup>+</sup> could also be used by ADP-ribosyl cyclases (ARCs) to generate NAADP that can mobilize intracellular Ca<sup>2+</sup> stores.

ROS generation, thus disrupting the 'Central Regulatory Network', leading to aging and numerous diseases. Future studies into the interactions between oxidative stress and the 'Central Regulatory Network' may further elucidate fundamental biological mechanisms.

Increasing evidence has suggested that NAD<sup>+</sup> is the central molecule in the metabolism and biological functions of NAD<sup>+</sup>, NADH, NADP<sup>+</sup>, and NADPH: out of these four molecules, NAD<sup>+</sup> could be the only one that can be *de novo* synthesized, while the generation of NADH, NADP<sup>+</sup>, and NADPH essentially requires NAD<sup>+</sup> as the original precursor. NAD<sup>+</sup> also appears to have particularly extensive biological functions compared with the other pyridine nucleotides. Therefore, it is tempting to propose that NAD<sup>+</sup> is the pivotal molecule in these pyridine nucleotides.

Whereas there have been numerous significant findings about the metabolism and biological functions of NAD and NADP during the last 20 years, these findings have also raised many questions that need to be answered by future studies. The following research directions may be of particular interest:

First, recent studies have suggested the presence of new NAD/NADP metabolic machineries in various subcellular organelles as well as extracellular space. It is of significance to further elucidate the regulation and biological significance of these machineries.

Second, NADKs play key roles in the balance between the NAD pool and the NADP pool. It is warranted to determine the roles of NADKs in modulating NAD-dependent and NADP-dependent biological activities under both physiological and pathological conditions.

Third, several studies have suggested close interactions among NAD-generating enzymes and NAD-dependent enzymes, such as that between PARP-1 and NMNAT-1. Future studies are needed to further determine the interactions among these proteins, and to determine the effects of these interactions on cell death, aging, and diseases.

Fourth, increasing evidence has indicated that multiple metabolic products of NAD<sup>+</sup>, including cyclic ADP-ribose, NAADP, ADP-ribose, and O-acetyl-ADP-ribose, are regulators of calcium homeostasis. It is warranted to determine the interactions among these regulators of calcium homeostasis.

Fifth, it is of great interest to determine the regulation of NADH shuttling and NAD transport across the plasma membranes of cells under physiological and pathological conditions.

Sixth, it is expected that future studies regarding the roles of NADPH oxidase in biological and pathological processes would yield ample information for understanding both basic biology and pathogenesis of many diseases.

Seventh, it is warranted to further determine the therapeutic potential of NAD<sup>+</sup> precursors, NAD and NADP for various diseases.

## ACKNOWLEDGMENTS

This work is supported by grants from Department of Defense, Department of Veterans Affairs, and American Heart Association (to WY).

## ABBREVIATIONS

AD, Alzheimer's disease; AIF, apoptosis-inducing factor; ART, mono(ADP-ribosyl)transferases; IP<sub>3</sub>, inositol 1,4,5-triphosphate; IDPc, cytosolic NADP<sup>+</sup>-dependent isocitrate dehydrogenases; IDPm, NADP<sup>+</sup>-dependent isocitrate dehydrogenases; MAS; MEPc, cytosolic NADP<sup>+</sup>-dependent malic enzyme; MEPm, mitochondrial NADP<sup>+</sup>-dependent malic enzyme; MPT, mitochondrial permeability transition; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; NAADP, nicotinic acid adenine dinucleotide phosphate; NAD<sup>+</sup>, nicotinamide adenine dinucleotide; NADH, reduced adenine dinucleotide; NADP<sup>+</sup>, nicotinamide adenine dinucleotide phosphate; NADPH, reduced nicotinamide adenine dinucleotide phosphate; Nampt, nicotinamide phosphoribosyltransferase; NMNAT, nicotinamide mononucleotide adenylyltransferase; PARG, poly(ADP-ribose) glycohydrolase; PARP-1, poly(ADP-ribose) polymerase-1; PD, Parkinson's disease; ROS, reactive oxygen species; TCA cycle, tricarboxylic acid cycle; TH, transhydrogenase; Wld(S), Wallerian degeneration slow.

## REFERENCES

1. Abramov AY, Canevari L, and Duchon MR. Beta-amyloid peptides induce mitochondrial dysfunction and oxidative stress in astrocytes and death of neurons through activation of NADPH oxidase. *J Neurosci* 24: 565–575, 2004.
2. Abramov AY and Duchon MR. The role of an astrocytic NADPH oxidase in the neurotoxicity of amyloid beta peptides. *Philos Trans R Soc Lond B Biol Sci* 360: 2309–2314, 2005.
3. Abramov AY, Scorziello A, and Duchon MR. Three distinct mechanisms generate oxygen free radicals in neurons and contribute to cell death during anoxia and reoxygenation. *J Neurosci* 27: 1129–1138, 2007.
4. Aksoy P, White TA, Thompson M, and Chini EN. Regulation of intracellular levels of NAD: a novel role for CD38. *Biochem Biophys Res Commun* 345: 1386–1392, 2006.
5. Alano CC, Ying W, and Swanson RA. Poly(ADP-ribose) polymerase-1-mediated cell death in astrocytes requires NAD<sup>+</sup> depletion and mitochondrial permeability transition. *J Biol Chem* 279: 18895–18902, 2004.
6. Alano CC and Swanson RA. Players in the PARP-1 cell-death pathway: JNK1 joins the cast. *Trends Biochem Sci* 31: 309–311, 2006.
7. Alano CC, Tran A, Tao R, Ying W, Karliner JS, and Swanson RA. Cell-type differences in NAD<sup>+</sup> compartmentalization: A comparison of neurons, astrocytes, and cardiac myocytes. *J Neurosci Res*, (Epub ahead of print).
8. Amiri KI, Ha HC, Smulson ME, and Richmond A. Differential regulation of CXC ligand 1 transcription in melanoma cell lines by poly(ADP-ribose) polymerase-1. *Oncogene* 25: 7714–7722, 2006.
9. Anderson JM, Charbonneau H, Jones HP, McCann RO, and Cormier MJ. Characterization of the plant nicotinamide adenine dinucleotide kinase activator protein and its identification as calmodulin. *Biochemistry* 19: 3113–3120, 1980.
10. Anderson RM, Bitterman KJ, Wood JG, Medvedik O, and Sinclair DA. Nicotinamide and PNC1 govern lifespan extension by calorie restriction in *Saccharomyces cerevisiae*. *Nature* 423: 181–185, 2003.
11. Andrabi SA, Kim NS, Yu SW, Wang H, Koh DW, Sasaki M, Klaus JA, Otsuka T, Zhang Z, Koehler RC, Hurn PD, Poirier GG, Dawson VL, and Dawson TM. Poly(ADP-ribose) (PAR) polymer is a death signal. *Proc Natl Acad Sci USA* 103: 18308–18313, 2006.

12. Andradi TB, Blazovics A, Szabo G, Vahl CF, and Hagl S. Poly(ADP-ribose) polymerase inhibitor PJ-34 reduces mesenteric vascular injury induced by experimental cardiopulmonary bypass with cardiac arrest. *Am J Physiol Heart Circ Physiol* 288: H2972–2978, 2005.
13. Andreone TL, O'Connor M, Denenberg A, Hake PW, and Zingarelli B. Poly(ADP-ribose) polymerase-1 regulates activation of activator protein-1 in murine fibroblasts. *J Immunol* 170: 2113–2120, 2003.
14. Araki T, Sasaki Y, and Milbrandt J. Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. *Science* 305: 1010–1013, 2004.
15. Arner ES and Holmgren A. Physiological functions of thioredoxin and thioredoxin reductase. *Eur J Biochem* 267: 6102–6109, 2000.
16. Arner ES and Holmgren A. The thioredoxin system in cancer. *Semin Cancer Biol* 16: 420–426, 2006.
17. Aswad F, Kawamura H, and Dennert G. High sensitivity of CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cells to extracellular metabolites nicotinamide adenine dinucleotide and ATP: a role for P2X7 receptors. *J Immunol* 175: 3075–3083, 2005.
18. Avalos JL, Bever KM, and Wolberger C. Mechanism of sirtuin inhibition by nicotinamide: altering the NAD<sup>+</sup> cosubstrate specificity of a Sir2 enzyme. *Mol Cell* 17: 855–868, 2005.
19. Ayoub IA, Lee EJ, Ogilvy CS, Beal MF, and Maynard KI. Nicotinamide reduces infarction up to two hours after the onset of permanent focal cerebral ischemia in Wistar rats. *Neurosci Lett* 259: 21–24, 1999.
20. Ayoub IA and Maynard KI. Therapeutic window for nicotinamide following transient focal cerebral ischemia. *Neuroreport* 13: 213–216, 2002.
21. Babior BM. NADPH oxidase. *Curr Opin Immunol* 16: 42–47, 2004.
22. Bae J, Donigian JR, and Hsueh AJ. Tankyrase 1 interacts with Mcl-1 proteins and inhibits their regulation of apoptosis. *J Biol Chem* 278: 5195–5204, 2003.
23. Bakondi E, Bai P, Erdelyi K, Szabo C, Gergely P, and Virag L. Cytoprotective effect of gallotannin in oxidatively stressed Ha-CaT keratinocytes: the role of poly(ADP-ribose) metabolism. *Exp Dermatol* 13: 170–178, 2004.
24. Beal MF. Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment. *J Bioenerg Biomembr* 36: 381–386, 2004.
25. Beck A, Kolisek M, Bagley LA, Fleig A, and Penner R. Nicotinic acid adenine dinucleotide phosphate and cyclic ADP-ribose regulate TRPM2 channels in T lymphocytes. *FASEB J* 20: 962–964, 2006.
26. Bedard K and Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. *Physiol Rev* 87: 245–313, 2007.
27. Belenky P, Bogan KL, and Brenner C. NAD<sup>+</sup> metabolism in health and disease. *Trends Biochem Sci* 32: 12–19, 2007.
28. Belenky P, Racette FG, Bogan KL, McClure JM, Smith JS, and Brenner C. Nicotinamide riboside promotes Sir2 silencing and extends lifespan via Nrk and Uhr1/Pnp1/Meu1 pathways to NAD<sup>+</sup>. *Cell* 129: 473–484, 2007.
29. Berger F, Ramirez—Hernandez MH, and Ziegler M. The new life of a centenarian: signalling functions of NAD(P). *Trends Biochem Sci* 29: 111–118, 2004.
30. Berger F, Lau C, Dahlmann M, and Ziegler M. Subcellular compartmentation and differential catalytic properties of the three human nicotinamide mononucleotide adenylyltransferase isoforms. *J Biol Chem* 280: 36334–36341, 2005.
31. Berger F, Lau C, and Ziegler M. Regulation of poly(ADP-ribose) polymerase 1 activity by the phosphorylation state of the nuclear NAD biosynthetic enzyme NMN adenylyl transferase 1. *Proc Natl Acad Sci USA* 104: 3765–3770, 2007.
32. Berger SJ, Manory I, Sudar DC, and Berger NA. Induction of the pyridine nucleotide synthesis pathway in mitogen-stimulated human T-lymphocytes. *Exp Cell Res* 169: 149–157, 1987.
33. Billington RA, Bruzzone S, De Flora A, Genazzani AA, Koch—Nolte F, Ziegler M, and Zocchi E. Emerging functions of extracellular pyridine nucleotides. *Mol Med* 12: 324–327, 2006.
34. Birkmayer JG, Vrecco C, Volc D, and Birkmayer W. Nicotinamide adenine dinucleotide (NADH)—a new therapeutic approach to Parkinson's disease. Comparison of oral and parenteral application. *Acta Neurol Scand Suppl* 146: 32–35, 1993.
35. Blander G and Guarente L. The Sir2 family of protein deacetylases. *Annu Rev Biochem* 73: 417–435, 2004.
36. Blasco MA. Telomeres and human disease: ageing, cancer and beyond. *Nat Rev Genet* 6: 611–622, 2005.
37. Blenn C, Althaus FR, and Malanga M. Poly(ADP-ribose) glycohydrolase silencing protects against H<sub>2</sub>O<sub>2</sub>-induced cell death. *Biochem J* 396:419–429, 2006.
38. Borutaite V, Hope H, and Brown GC. Arachidonate and NADPH oxidase synergise with iNOS to induce death in macrophages: mechanisms of inflammatory degeneration. *Pharmacol Rep* 58 Suppl: 96–102, 2006.
39. Boulares AH, Zoltoski AJ, Sherif ZA, Yakovlev AG, and Smulson ME. The Poly(ADP-ribose) polymerase-1-regulated endonuclease DNAS1L3 is required for etoposide-induced internucleosomal DNA fragmentation and increases etoposide cytotoxicity in transfected osteosarcoma cells. *Cancer Res* 62: 4439–4444, 2002.
40. Brewer KL and Hardin JS. Neuroprotective effects of nicotinamide after experimental spinal cord injury. *Acad Emerg Med* 11: 125–130, 2004.
41. Brumaghim JL, Li Y, Henle E, and Linn S. Effects of hydrogen peroxide upon nicotinamide nucleotide metabolism in *Escherichia coli*: changes in enzyme levels and nicotinamide nucleotide pools and studies of the oxidation of NAD(P)H by Fe(III). *J Biol Chem* 278: 42495–42504, 2003.
42. Bruzzone S, Guida L, Zocchi E, Franco L, and De Flora A. Connexin 43 hemi channels mediate Ca<sup>2+</sup>-regulated transmembrane NAD<sup>+</sup> fluxes in intact cells. *FASEB J* 15: 10–12, 2001.
43. Bruzzone S, De Flora A, Usai C, Graeff R, and Lee HC. Cyclic ADP-ribose is a second messenger in the lipopolysaccharide-stimulated proliferation of human peripheral blood mononuclear cells. *Biochem J* 375: 395–403, 2003.
44. Burkle A. Poly(ADP-ribose). The most elaborate metabolite of NAD<sup>+</sup>. *FEBS J* 272: 4576–4589, 2005.
45. Burkle A, Diefenbach J, Brabeck C, and Beneke S. Ageing and PARP. *Pharmacol Res* 52: 93–99, 2005.
46. Burns D, Ying W, Garnier P, and Swanson RA. Decreases expression of the full-length poly(ADP-ribose) glycohydrolase by antisense oligonucleotide treatment prevents PARP-1-mediated astrocyte death. *34th American Society for Neurosciences Annual Meeting Abstracts*, 2004.
47. Cadenas E and Davies KJ. Mitochondrial free radical generation, oxidative stress, and aging. *Free Radic Biol Med* 29: 222–230, 2000.
48. Cecchi C, Fiorillo C, Sorbi S, Latorraca S, Nacmias B, Bagnoli S, Nassi P, and Liguri G. Oxidative stress and reduced antioxidant defenses in peripheral cells from familial Alzheimer's patients. *Free Radic Biol Med* 33: 1372–1379, 2002.
49. Chan PH. Role of oxidants in ischemic brain damage. *Stroke* 27: 1124–1129, 1996.
50. Chan PH. Reactive oxygen radicals in signaling and damage in the ischemic brain. *J Cereb Blood Flow Metab* 21: 2–14, 2001.
51. Chang WJ and Alvarez—Gonzalez R. The sequence-specific DNA binding of NF-kappa B is reversibly regulated by the auto-modification reaction of poly (ADP-ribose) polymerase 1. *J Biol Chem* 276: 47664–47670, 2001.
52. Chen WY, Wang DH, Yen RC, Luo J, Gu W, and Baylin SB. Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. *Cell* 123: 437–448, 2005.
53. Cherednichenko G, Zima AV, Feng W, Schaefer S, Blatter LA, and Pessah IN. NADH oxidase activity of rat cardiac sarcoplasmic reticulum regulates calcium-induced calcium release. *Circ Res* 94: 478–486, 2004.
54. Chi NW and Lodish HF. Tankyrase is a golgi-associated mitogen-activated protein kinase substrate that interacts with IRAP in GLUT4 vesicles. *J Biol Chem* 275: 38437–38444, 2000.
55. Chong ZZ, Lin SH, and Maiese K. Nicotinamide modulates mitochondrial membrane potential and cysteine protease activity

- during cerebral vascular endothelial cell injury. *J Vasc Res* 39: 131–147, 2002.
56. Chong ZZ, Lin SH, and Maiese K. The NAD<sup>+</sup> precursor nicotinamide governs neuronal survival during oxidative stress through protein kinase B coupled to FOXO3a and mitochondrial membrane potential. *J Cereb Blood Flow Metab* 24: 728–743, 2004.
  57. Chong ZZ, Lin SH, Li F, and Maiese K. The sirtuin inhibitor nicotinamide enhances neuronal cell survival during acute anoxic injury through AKT, BAD, PARP, and mitochondrial associated “anti-apoptotic” pathways. *Curr Neurovasc Res* 2: 271–285, 2005.
  58. Chuang DM, Hough C, and Senatorov VV. Glyceraldehyde-3-phosphate dehydrogenase, apoptosis, and neurodegenerative diseases. *Annu Rev Pharmacol Toxicol* 45: 269–290, 2005.
  59. Cohen—Armon M, VISOCHek L, Rozensal D, Kalal A, Geistrikh I, Klein R, Bendetz—Nezer S, Yao Z, and Seger R. DNA-independent PARP-1 activation by phosphorylated ERK2 increases Elk1 activity: a link to histone acetylation. *Mol Cell* 25: 297–308, 2007.
  60. Coleman M. Axon degeneration mechanisms: commonality amid diversity. *Nat Rev Neurosci* 6: 889–898, 2005.
  61. Comte B, Vincent G, Bouchard B, Benderdour M, and Des Rosiers C. Reverse flux through cardiac NADP<sup>+</sup>-isocitrate dehydrogenase under normoxia and ischemia. *Am J Physiol Heart Circ Physiol* 283: H1505–1514, 2002.
  62. Conforti L, Fang G, Beirowski B, Wang MS, Sorci L, Asress S, Adalbert R, Silva A, Bridge K, Huang XP, Magni G, Glass JD, and Coleman MP. NAD<sup>+</sup> and axon degeneration revisited: Nmnat1 cannot substitute for Wld(S) to delay Wallerian degeneration. *Cell Death Differ* 14: 116–127, 2007.
  63. Corda D and Di Girolamo M. Mono-ADP-ribosylation: a tool for modulating immune response and cell signaling. *Sci STKE* 2002: PE53, 2002.
  64. Corda D and Di Girolamo M. Functional aspects of protein mono-ADP-ribosylation. *EMBO J* 22: 1953–1958, 2003.
  65. Cormier MJ, Charbonneau H, and Jarrett HW. Plant and fungal calmodulin: Ca<sup>2+</sup>-dependent regulation of plant NAD kinase. *Cell Calcium* 2: 313–331, 1981.
  66. Cosi C, Colpaert F, Koek W, Degryse A, and Marien M. Poly(ADP-ribose) polymerase inhibitors protect against MPTP-induced depletions of striatal dopamine and cortical noradrenaline in C57B1/6 mice. *Brain Res* 729: 264–269, 1996.
  67. Coughlan MT, Cooper ME, and Forbes JM. Renal microvascular injury in diabetes: RAGE and redox signaling. *Antioxid Redox Signal* 9: 331–342, 2007.
  68. Cozzi A, Cipriani G, Fossati S, Faraco G, Formentini L, Min W, Cortes U, Wang ZQ, Moroni F, and Chiarugi A. Poly(ADP-ribose) accumulation and enhancement of posts ischemic brain damage in 110-kDa poly(ADP-ribose) glycohydrolase null mice. *J Cereb Blood Flow Metab* 26: 684–695, 2006.
  69. Crompton M, Virji S, Doyle V, Johnson N, and Ward JM. The mitochondrial permeability transition pore. *Biochem Soc Symp* 66: 167–179, 1999.
  70. Cuzzocrea S, Di Paola R, Mazzon E, Cortes U, Genovese T, Muia C, Li W, Xu W, Li JH, Zhang J, and Wang ZQ. PARG activity mediates intestinal injury induced by splanchnic artery occlusion and reperfusion. *FASEB J* 19: 558–566, 2005.
  71. Cuzzocrea S and Wang ZQ. Role of poly(ADP-ribose) glycohydrolase (PARG) in shock, ischemia and reperfusion. *Pharmacol Res* 52: 100–108, 2005.
  72. Cuzzocrea S, Genovese T, Mazzon E, Crisafulli C, Min W, Di Paola R, Muia C, Li JH, Esposito E, Bramanti P, Xu W, Massuda E, Zhang J, and Wang ZQ. Poly(ADP-ribose) glycohydrolase activity mediates post-traumatic inflammatory reaction after experimental spinal cord trauma. *J Pharmacol Exp Ther* 319: 127–138, 2006.
  73. Cuzzocrea S, Mazzon E, Genovese T, Crisafulli C, Min WK, Di Paola R, Muia C, Li JH, Malleo G, Xu W, Massuda E, Esposito E, Zhang J, and Wang ZQ. Role of poly(ADP-ribose) glycohydrolase in the development of inflammatory bowel disease in mice. *Free Radic Biol Med* 42: 90–105, 2007.
  74. D’Amours D, Desnoyers S, D’Silva I, and Poirier GG. Poly(ADP-ribosylation) reactions in the regulation of nuclear functions. *Biochem J* 342: 249–268, 1999.
  75. Dai JM, Wang ZY, Sun DC, Lin RX, and Wang SQ. SIRT1 interacts with p73 and suppresses p73-dependent transcriptional activity. *J Cell Physiol* 210: 161–166, 2007.
  76. Daugas E, Susin SA, Zamzami N, Ferri KF, Irinopoulou T, Larochette N, Prevost MC, Leber B, Andrews D, Penninger J, and Kroemer G. Mitochondrio-nuclear translocation of AIF in apoptosis and necrosis. *FASEB J* 14: 729–739, 2000.
  77. Davidovic L, Vodenicharov M, Affar EB, and Poirier GG. Importance of poly(ADP-ribose) glycohydrolase in the control of poly(ADP-ribose) metabolism. *Exp Cell Res* 268: 7–13, 2001.
  78. Demarin V, Podobnik SS, Storga—Tomic D, and Kay G. Treatment of Alzheimer’s disease with stabilized oral nicotinamide adenine dinucleotide: a randomized, double-blind study. *Drugs Exp Clin Res* 30: 27–33, 2004.
  79. Denu JM. The Sir 2 family of protein deacetylases. *Curr Opin Chem Biol* 9: 431–440, 2005.
  80. Des Rosiers C, Fernandez CA, David F, and Brunengraber H. Reversibility of the mitochondrial isocitrate dehydrogenase reaction in the perfused rat liver. Evidence from isotopomer analysis of citric acid cycle intermediates. *J Biol Chem* 269: 27179–27182, 1994.
  81. Di Girolamo M, Dani N, Stilla A, and Corda D. Physiological relevance of the endogenous mono(ADP-ribosylation) of cellular proteins. *FEBS J* 272: 4565–4575, 2005.
  82. Di Lisa F, Menabo R, Canton M, Barile M, and Bernardi P. Opening of the mitochondrial permeability transition pore causes depletion of mitochondrial and cytosolic NAD<sup>+</sup> and is a causative event in the death of myocytes in posts ischemic reperfusion of the heart. *J Biol Chem* 276: 2571–2575, 2001.
  83. Di Lisa F and Ziegler M. Pathophysiological relevance of mitochondria in NAD(+) metabolism. *FEBS Lett* 492: 4–8, 2001.
  84. Di Meglio S, Denegri M, Vallefuoco S, Tramontano F, Scovassi AI, and Quesada P. Poly(ADPR) polymerase-1 and poly(ADPR) glycohydrolase level and distribution in differentiating rat germinal cells. *Mol Cell Biochem* 248: 85–91, 2003.
  85. Du L, Zhang X, Han YY, Burke NA, Kochanek PM, Watkins SC, Graham SH, Carcillo JA, Szabo C, and Clark RS. Intra-mitochondrial poly(ADP-ribosylation) contributes to NAD<sup>+</sup> depletion and cell death induced by oxidative stress. *J Biol Chem* 278: 18426–18433, 2003.
  86. Dworakowski R, Anilkumar N, Zhang M, and Shah AM. Redox signalling involving NADPH oxidase-derived reactive oxygen species. *Biochem Soc Trans* 34: 960–964, 2006.
  87. Eliasson MJ, Sampei K, Mandir AS, Hurn PD, Traystman RJ, Bao J, Pieper A, Wang ZQ, Dawson TM, Snyder SH, and Dawson VL. Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia. *Nat Med* 3: 1089–1095, 1997.
  88. Endres M, Wang ZQ, Namura S, Waeber C, and Moskowitz MA. Ischemic brain injury is mediated by the activation of poly(ADP-ribose)polymerase. *J Cereb Blood Flow Metab* 17: 1143–1151, 1997.
  89. Fliegert R, Gasser A, and Guse AH. Regulation of calcium signalling by adenine-based second messengers. *Biochem Soc Trans* 35: 109–114, 2007.
  90. Fonfria E, Marshall IC, Benham CD, Boyfield I, Brown JD, Hill K, Hughes JP, Skaper SD, and McNulty S. TRPM2 channel opening in response to oxidative stress is dependent on activation of poly(ADP-ribose) polymerase. *Br J Pharmacol* 143: 186–192, 2004.
  91. Fonfria E, Marshall IC, Boyfield I, Skaper SD, Hughes JP, Owen DE, Zhang W, Miller BA, Benham CD, and McNulty S. Amyloid beta-peptide(1–42) and hydrogen peroxide-induced toxicity are mediated by TRPM2 in rat primary striatal cultures. *J Neurochem* 95: 715–723, 2005.
  92. Ford E, Voit R, Liszt G, Magin C, Grummt I, and Guarente L. Mammalian Sir2 homolog SIRT7 is an activator of RNA polymerase I transcription. *Genes Dev* 20: 1075–1080, 2006.
  93. Ford J, Jiang M, and Milner J. Cancer-specific functions of SIRT1 enable human epithelial cancer cell growth and survival. *Cancer Res* 65: 10457–10463, 2005.
  94. Freeman H, Shimomura K, Cox RD, and Ashcroft FM. Nicotinamide nucleotide transhydrogenase: a link between insulin secretion, glucose metabolism and oxidative stress. *Biochem Soc Trans* 34: 806–810, 2006.

95. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa Y, and Shimomura I. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. *Science* 307: 426–430, 2005.
96. Galione A. NAADP, a new intracellular messenger that mobilizes  $Ca^{2+}$  from acidic stores. *Biochem Soc Trans* 34: 922–926, 2006.
97. Gao H, Coyle DL, Meyer—Ficca ML, Meyer RG, Jacobson EL, Wang ZQ, and Jacobson MK. Altered poly(ADP-ribose) metabolism impairs cellular responses to genotoxic stress in a hypomorphic mutant of poly(ADP-ribose) glycohydrolase. *Exp Cell Res* 313: 984–996, 2007.
98. Gasser A, Glassmeier G, Fliegert R, Langhorst MF, Meinke S, Hein D, Kruger S, Weber K, Heiner I, Oppenheimer N, Schwarz JR, and Guse AH. Activation of T cell calcium influx by the second messenger ADP-ribose. *J Biol Chem* 281: 2489–2496, 2006.
99. Gendron MC, Schrantz N, Metivier D, Kroemer G, Maciorowska Z, Sureau F, Koester S, and Petit PX. Oxidation of pyridine nucleotides during Fas- and ceramide-induced apoptosis in Jurkat cells: correlation with changes in mitochondria, glutathione depletion, intracellular acidification and caspase 3 activation. *Biochem J* 353: 357–367, 2001.
100. Genovese T, Di Paola R, Catalano P, Li JH, Xu W, Massuda E, Caputi AP, Zhang J, and Cuzzocrea S. Treatment with a novel poly(ADP-ribose) glycohydrolase inhibitor reduces development of septic shock-like syndrome induced by zymosan in mice. *Crit Care Med* 32: 1365–1374, 2004.
101. Gill PS and Wilcox CS. NADPH oxidases in the kidney. *Antioxid Redox Signal* 8: 1597–1607, 2006.
102. Grabowska D and Chelstowska A. The ALD6 gene product is indispensable for providing NADPH in yeast cells lacking glucose-6-phosphate dehydrogenase activity. *J Biol Chem* 278: 13984–13988, 2003.
103. Graziani G, Battaini F, and Zhang J. PARP-1 inhibition to treat cancer, ischemia, inflammation. *Pharmacol Res* 52: 1–4, 2005.
104. Green DR and Reed JC. Mitochondria and apoptosis. *Science* 281: 1309–1312, 1998.
105. Grose JH, Joss L, Velick SF, and Roth JR. Evidence that feedback inhibition of NAD kinase controls responses to oxidative stress. *Proc Natl Acad Sci USA* 103: 7601–7606, 2006.
106. Grube K and Burkle A. Poly(ADP-ribose) polymerase activity in mononuclear leukocytes of 13 mammalian species correlates with species-specific life span. *Proc Natl Acad Sci USA* 89: 11759–11763, 1992.
107. Grubisha O, Rafta LA, Takanishi CL, Xu X, Tong L, Perraud AL, Scharenberg AM, and Denu JM. Metabolite of SIR2 reaction modulates TRPM2 ion channel. *J Biol Chem* 281: 14057–14065, 2006.
108. Guse AH. Second messenger function and the structure-activity relationship of cyclic adenosine diphosphoribose (cADPR). *FEBS J* 272: 4590–4597, 2005.
109. Guzik TJ, West NE, Pillai R, Taggart DP, and Channon KM. Nitric oxide modulates superoxide release and peroxynitrite formation in human blood vessels. *Hypertension* 39: 1088–1094, 2002.
110. Guzik TJ, Korbut R, and Adamek—Guzik T. Nitric oxide and superoxide in inflammation and immune regulation. *J Physiol Pharmacol* 54: 469–487, 2003.
111. Ha HC, Hester LD, and Snyder SH. Poly(ADP-ribose) polymerase-1 dependence of stress-induced transcription factors and associated gene expression in glia. *Proc Natl Acad Sci USA* 99: 3270–3275, 2002.
112. Hahn WC. Role of telomeres and telomerase in the pathogenesis of human cancer. *J Clin Oncol* 21: 2034–2043, 2003.
113. Halliwell B and Gutteridge J. *Free Radicals in Biology and Medicine*. Oxford: Clarendon, 1989.
114. Hallows WC, Lee S, and Denu JM. Sirtuins deacetylate and activate mammalian acetyl-CoA synthetases. *Proc Natl Acad Sci USA* 103: 10230–10235, 2006.
115. Hara MR, Agrawal N, Kim SF, Cascio MB, Fujimuro M, Ozeki Y, Takahashi M, Cheah JH, Tankou SK, Hester LD, Ferris CD, Hayward SD, Snyder SH, and Sawa A. S-nitrosylated GAPDH initiates apoptotic cell death by nuclear translocation following Siah1 binding. *Nat Cell Biol* 7: 665–674, 2005.
116. Hara MR, Thomas B, Cascio MB, Bae BI, Hester LD, Dawson VL, Dawson TM, Sawa A, and Snyder SH. Neuroprotection by pharmacologic blockade of the GAPDH death cascade. *Proc Natl Acad Sci USA* 103: 3887–3889, 2006.
117. Hasmann M and Schemainda I. FK866, a highly specific non-competitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. *Cancer Res* 63: 7436–7442, 2003.
118. Hassa PO, Covic M, Hasan S, Imhof R, and Hottiger MO. The enzymatic and DNA binding activity of PARP-1 are not required for NF-kappa B coactivator function. *J Biol Chem* 276: 45588–45597, 2001.
119. Hensley K, Butterfield DA, Hall N, Cole P, Subramaniam R, Mark R, Mattson MP, Markesbery WR, Harris ME, Aksenov M, and et al. Reactive oxygen species as causal agents in the neurotoxicity of the Alzheimer's disease-associated amyloid beta peptide. *Ann NY Acad Sci* 786: 120–134, 1996.
120. Hitomi H, Fukui T, Moriwaki K, Matsubara K, Sun GP, Rahman M, Nishiyama A, Kiyomoto H, Kimura S, Ohmori K, Abe Y, and Kohno M. Synergistic effect of mechanical stretch and angiotensin II on superoxide production via NADPH oxidase in vascular smooth muscle cells. *J Hypertens* 24: 1089–1095, 2006.
121. Hwang JJ, Choi SY, and Koh JY. The role of NADPH oxidase, neuronal nitric oxide synthase and poly(ADP ribose) polymerase in oxidative neuronal death induced in cortical cultures by brain-derived neurotrophic factor and neurotrophin-4/5. *J Neurochem* 82: 894–902, 2002.
122. Ido Y. Pyridine nucleotide redox abnormalities in diabetes. *Antioxid Redox Signal* 9: 931–942, 2007.
123. Infanger DW, Sharma RV, and Davisson RL. NADPH oxidases of the brain: distribution, regulation, and function. *Antioxid Redox Signal* 8: 1583–1596, 2006.
124. Inoguchi T and Nawata H. NAD(P)H oxidase activation: a potential target mechanism for diabetic vascular complications, progressive beta-cell dysfunction and metabolic syndrome. *Curr Drug Targets* 6: 495–501, 2005.
125. Ischiropoulos H and al-Mehdi AB. Peroxynitrite-mediated oxidative protein modifications. *FEBS Lett* 364: 279–282, 1995.
126. Iwashita A, Yamazaki S, Mihara K, Hattori K, Yamamoto H, Ishida J, Matsuoka N, and Mutoh S. Neuroprotective effects of a novel poly(ADP-ribose) polymerase-1 inhibitor, 2-[3-[4-(4-chlorophenyl)-1-piperazinyl] propyl]-4(3H)-quinazolinone (FR255595), in an in vitro model of cell death and in mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. *J Pharmacol Exp Ther* 309: 1067–1078, 2004.
127. Jackson JB. Proton translocation by transhydrogenase. *FEBS Lett* 555: 176–177, 2003.
128. Jaeschke H, Kleinwaechter C, and Wendel A. NADH-dependent reductive stress and ferritin-bound iron in allyl alcohol-induced lipid peroxidation in vivo: the protective effect of vitamin E. *Chem Biol Interact* 81: 57–68, 1992.
129. Jia H, Yan T, Feng Y, Zeng C, Shi X, and Zhai Q. Identification of a critical site in Wld(s): essential for Nmnat enzyme activity and axon-protective function. *Neurosci Lett* 413: 46–51, 2007.
130. Jo SH, Son MK, Koh HJ, Lee SM, Song IH, Kim YO, Lee YS, Jeong KS, Kim WB, Park JW, Song BJ, and Huh TL. Control of mitochondrial redox balance and cellular defense against oxidative damage by mitochondrial NADP<sup>+</sup>-dependent isocitrate dehydrogenase. *J Biol Chem* 276: 16168–16176, 2001.
131. Ju BG, Lunyak VV, Perissi V, Garcia—Bassets I, Rose DW, Glass CK, and Rosenfeld MG. A topoisomerase IIbeta-mediated dsDNA break required for regulated transcription. *Science* 312: 1798–1802, 2006.
132. Kahraman S and Fiskum G. Anoxia-induced changes in pyridine nucleotide redox state in cortical neurons and astrocytes. *Neurochem Res* 32: 799–806, 2007.
133. Kaneko S, Wang J, Kaneko M, Yiu G, Hurrell JM, Chitnis T, Khoury SJ, and He Z. Protecting axonal degeneration by increasing nicotinamide adenine dinucleotide levels in experimental autoimmune encephalomyelitis models. *J Neurosci* 26: 9794–9804, 2006.

134. Kaplin AI, Snyder SH, and Linden DJ. Reduced nicotinamide adenine dinucleotide-selective stimulation of inositol 1,4,5-trisphosphate receptors mediates hypoxic mobilization of calcium. *J Neurosci* 16: 2002–2011, 1996.
135. Katoh A, Uenohara K, Akita M, and Hashimoto T. Early steps in the biosynthesis of NAD in Arabidopsis start with aspartate and occur in the plastid. *Plant Physiol* 141: 851–857, 2006.
136. Kauppinen TM, Chan WY, Suh SW, Wiggins AK, Huang EJ, and Swanson RA. Direct phosphorylation and regulation of poly(ADP-ribose) polymerase-1 by extracellular signal-regulated kinases 1/2. *Proc Natl Acad Sci USA* 103: 7136–7141, 2006.
137. Keller JN, Guo Q, Holtsberg FW, Bruce—Keller AJ, and Mattson MP. Increased sensitivity to mitochondrial toxin-induced apoptosis in neural cells expressing mutant presenilin-1 is linked to perturbed calcium homeostasis and enhanced oxyradical production. *J Neurosci* 18: 4439–4450, 1998.
138. Kil IS, Lee JH, Shin AH, and Park JW. Glycation-induced inactivation of NADP<sup>+</sup>-dependent isocitrate dehydrogenase: implications for diabetes and aging. *Free Radic Biol Med* 37: 1765–1778, 2004.
139. Kil IS, Shin SW, Yeo HS, Lee YS, and Park JW. Mitochondrial NADP<sup>+</sup>-dependent isocitrate dehydrogenase protects cadmium-induced apoptosis. *Mol Pharmacol* 70: 1053–1061, 2006.
140. Kim MY, Mauro S, Gevry N, Lis JT, and Kraus WL. NAD<sup>+</sup>-dependent modulation of chromatin structure and transcription by nucleosome binding properties of PARP-1. *Cell* 119: 803–814, 2004.
141. Kim MY, Zhang T, and Kraus WL. Poly(ADP-ribosylation) by PARP-1: 'PAR-laying' NAD<sup>+</sup> into a nuclear signal. *Genes Dev* 19: 1951–1967, 2005.
142. Kim YH and Koh JY. The role of NADPH oxidase and neuronal nitric oxide synthase in zinc-induced poly(ADP-ribose) polymerase activation and cell death in cortical culture. *Exp Neurol* 177: 407–418, 2002.
143. Kirkman HN and Gaetani GF. Catalase: a tetrameric enzyme with four tightly bound molecules of NADPH. *Proc Natl Acad Sci USA* 81: 4343–4347, 1984.
144. Kirsch M and De Groot H. NAD(P)H, a directly operating antioxidant? *FASEB J* 15: 1569–1574, 2001.
145. Klaidman L, Morales M, Kem S, Yang J, Chang ML, and Adams JD, Jr. Nicotinamide offers multiple protective mechanisms in stroke as a precursor for NAD<sup>+</sup>, as a PARP inhibitor and by partial restoration of mitochondrial function. *Pharmacology* 69: 150–157, 2003.
146. Kletzien RF, Harris PK, and Foellmi LA. Glucose-6-phosphate dehydrogenase: a "housekeeping" enzyme subject to tissue-specific regulation by hormones, nutrients, and oxidant stress. *FASEB J* 8: 174–181, 1994.
147. Koch—Nolte F, Adriouch S, Bannas P, Krebs C, Scheuplein F, Seman M, and Haag F. ADP-ribosylation of membrane proteins: unveiling the secrets of a crucial regulatory mechanism in mammalian cells. *Ann Med* 38: 188–199, 2006.
148. Koh HJ, Lee SM, Son BG, Lee SH, Ryoo ZY, Chang KT, Park JW, Park DC, Song BJ, Veech RL, Song H, and Huh TL. Cytosolic NADP<sup>+</sup>-dependent isocitrate dehydrogenase plays a key role in lipid metabolism. *J Biol Chem* 279: 39968–39974, 2004.
149. Kolthur—Seetharam U, Dantzer F, McBurney MW, de Murcia G, and Sassone—Corsi P. Control of AIF-mediated cell death by the functional interplay of SIRT1 and PARP-1 in response to DNA damage. *Cell Cycle* 5: 873–877, 2006.
150. Kroemer G, Zamzami N, and Susin SA. Mitochondrial control of apoptosis. *Immunol Today* 18: 44–51, 1997.
151. Kuhn FJ, Heiner I, and Luckhoff A. TRPM2: a calcium influx pathway regulated by oxidative stress and the novel second messenger ADP-ribose. *Pflugers Arch* 451: 212–219, 2005.
152. Kuhn W, Muller T, Winkel R, Danielczik S, Gerstner A, Hacker R, Mattern C, and Przuntek H. Parenteral application of NADH in Parkinson's disease: clinical improvement partially due to stimulation of endogenous levodopa biosynthesis. *J Neural Transm* 103: 1187–1193, 1996.
153. Kuroda J, Nakagawa K, Yamasaki T, Nakamura K, Takeya R, Kuribayashi F, Imajoh—Ohmi S, Igarashi K, Shibata Y, Sueishi K, and Sumimoto H. The superoxide-producing NAD(P)H oxidase Nox4 in the nucleus of human vascular endothelial cells. *Genes Cells* 10: 1139–1151, 2005.
154. Kusaka I, Kusaka G, Zhou C, Ishikawa M, Nanda A, Granger DN, Zhang JH, and Tang J. Role of AT1 receptors and NAD(P)H oxidase in diabetes-aggravated ischemic brain injury. *Am J Physiol Heart Circ Physiol* 286: H2442–2451, 2004.
155. La Piana G, Fransvea E, Marzulli D, and Lofrumento NE. Mitochondrial membrane potential supported by exogenous cytochrome c oxidation mimics the early stages of apoptosis. *Biochem Biophys Res Commun* 246: 556–561, 1998.
156. La Piana G, Marzulli D, Gorgoglione V, and Lofrumento NE. Porin and cytochrome oxidase containing contact sites involved in the oxidation of cytosolic NADH. *Arch Biochem Biophys* 436: 91–100, 2005.
157. Lafeber FP, Beukelman CJ, van den Worm E, van Roy JL, Vianen ME, van Roon JA, van Dijk H, and Bijlsma JW. Apocynin, a plant-derived, cartilage-saving drug, might be useful in the treatment of rheumatoid arthritis. *Rheumatology (Oxford)* 38: 1088–1093, 1999.
158. LaPlaca MC, Zhang J, Raghupathi R, Li JH, Smith F, Bareyre FM, Snyder SH, Graham DI, and McIntosh TK. Pharmacologic inhibition of poly(ADP-ribose) polymerase is neuroprotective following traumatic brain injury in rats. *J Neurotrauma* 18: 369–376, 2001.
159. Lee HC. Physiological functions of cyclic ADP-ribose and NAADP as calcium messengers. *Annu Rev Pharmacol Toxicol* 41: 317–345, 2001.
160. Lee HC. Multiplicity of Ca<sup>2+</sup> messengers and Ca<sup>2+</sup> stores: a perspective from cyclic ADP-ribose and NAADP. *Curr Mol Med* 4: 227–237, 2004.
161. Lee JH and Park JW. Oxalomalate regulates ionizing radiation-induced apoptosis in mice. *Free Radic Biol Med* 42: 44–51, 2007.
162. Lee SH, Jo SH, Lee SM, Koh HJ, Song H, Park JW, Lee WH, and Huh TL. Role of NADP<sup>+</sup>-dependent isocitrate dehydrogenase (NADP<sup>+</sup>-ICDH) on cellular defence against oxidative injury by gamma-rays. *Int J Radiat Biol* 80: 635–642, 2004.
163. Lee SM, Koh HJ, Park DC, Song BJ, Huh TL, and Park JW. Cytosolic NADP<sup>+</sup>-dependent isocitrate dehydrogenase status modulates oxidative damage to cells. *Free Radic Biol Med* 32: 1185–1196, 2002.
164. Lehninger AL. Phosphorylation coupled to oxidation of dihydropyridine nucleotide. *J Biol Chem* 190: 345–359, 1951.
165. Lemasters JJ, Nieminen AL, Qian T, Trost LC, Elmore SP, Nishimura Y, Crowe RA, Cascio WE, Bradham CA, Brenner DA, and Herman B. The mitochondrial permeability transition in cell death: a common mechanism in necrosis, apoptosis and autophagy. *Biochim Biophys Acta* 1366: 177–196, 1998.
166. Lerner F, Niere M, Ludwig A, and Ziegler M. Structural and functional characterization of human NAD kinase. *Biochem Biophys Res Commun* 288: 69–74, 2001.
167. Leto TL and Geiszt M. Role of Nox family NADPH oxidases in host defense. *Antioxid Redox Signal* 8: 1549–1561, 2006.
168. Li F, Chong ZZ, and Maiese K. Cell Life versus cell longevity: the mysteries surrounding the NAD<sup>+</sup> precursor nicotinamide. *Curr Med Chem* 13: 883–895, 2006.
169. Li J, Baud O, Vartanian T, Volpe JJ, and Rosenberg PA. Peroxynitrite generated by inducible nitric oxide synthase and NADPH oxidase mediates microglial toxicity to oligodendrocytes. *Proc Natl Acad Sci USA* 102: 9936–9941, 2005.
170. Li M, Naidu P, Yu Y, Berger NA, and Kannan P. Dual regulation of AP-2alpha transcriptional activation by poly(ADP-ribose) polymerase-1. *Biochem J* 382: 323–329, 2004.
171. Li Y, Oh HJ, and Lau YF. The poly(ADP-ribose) polymerase 1 interacts with Sry and modulates its biological functions. *Mol Cell Endocrinol* 257–258: 35–46, 2006.
172. Liang M, Chini EN, Cheng J, and Dousa TP. Synthesis of NAADP and cADPR in mitochondria. *Arch Biochem Biophys* 371: 317–325, 1999.
173. Lin SJ, Ford E, Haigis M, Liszt G, and Guarente L. Calorie restriction extends yeast life span by lowering the level of NADH. *Genes Dev* 18: 12–16, 2004.

174. Lipton SA and Bossy—Wetzel E. Dueling activities of AIF in cell death versus survival: DNA binding and redox activity. *Cell* 111: 147–150, 2002.
175. Lis JT and Kraus WL. Promoter cleavage: a topolIbeta and PARP-1 collaboration. *Cell* 125: 1225–1227, 2006.
176. Love S, Barber R, and Wilcock GK. Neuronal accumulation of poly(ADP-ribose) after brain ischaemia. *Neuropathol Appl Neurobiol* 25: 98–103, 1999.
177. Lu H, Burns D, Garnier P, Wei G, Zhu K, and Ying W. P2X7 receptors mediate NADH transport across the plasma membranes of astrocytes. *Biochem Biophys Res Commun* 362: 946–950, 2007.
178. Lu XC, Massuda E, Lin Q, Li W, Li JH, and Zhang J. Post-treatment with a novel PARG inhibitor reduces infarct in cerebral ischemia in the rat. *Brain Res* 978: 99–103, 2003.
179. Luo J, Nikolaev AY, Imai S, Chen D, Su F, Shiloh A, Guarente L, and Gu W. Negative control of p53 by Sir2alpha promotes cell survival under stress. *Cell* 107: 137–148, 2001.
180. Maeng O, Kim YC, Shin HJ, Lee JO, Huh TL, Kang KI, Kim YS, Paik SG, and Lee H. Cytosolic NADP<sup>+</sup>-dependent isocitrate dehydrogenase protects macrophages from LPS-induced nitric oxide and reactive oxygen species. *Biochem Biophys Res Commun* 317: 558–564, 2004.
181. Magni G, Amici A, Emanuelli M, Raffaelli N, and Ruggieri S. Enzymology of NAD<sup>+</sup> synthesis. *Adv Enzymol Relat Areas Mol Biol* 73: 135–182, 1999.
182. Magni G, Amici A, Emanuelli M, Orsomando G, Raffaelli N, and Ruggieri S. Enzymology of NAD<sup>+</sup> homeostasis in man. *Cell Mol Life Sci* 61: 19–34, 2004.
183. Maiese K and Chong ZZ. Nicotinamide: necessary nutrient emerges as a novel cytoprotectant for the brain. *Trends Pharmacol Sci* 24: 228–232, 2003.
184. Mandir AS, Przedborski S, Jackson—Lewis V, Wang ZQ, Simbulan—Rosenthal CM, Smulson ME, Hoffman BE, Guastella DB, Dawson VL, and Dawson TM. Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism. *Proc Natl Acad Sci USA* 96: 5774–5779, 1999.
185. Mandir AS, Simbulan—Rosenthal CM, Poitras MF, Lumpkin JR, Dawson VL, Smulson ME, and Dawson TM. A novel in vivo post-translational modification of p53 by PARP-1 in MPTP-induced parkinsonism. *J Neurochem* 83: 186–192, 2002.
186. Martin—Oliva D, O'Valle F, Munoz—Gamez JA, Valenzuela MT, Nunez MI, Aguilar M, Ruiz de Almodovar JM, Garcia del Moral R, and Oliver FJ. Crosstalk between PARP-1 and NF-kappaB modulates the promotion of skin neoplasia. *Oncogene* 23: 5275–5283, 2004.
187. Martin—Oliva D, Aguilar—Quesada R, O'Valle F, Munoz—Gamez JA, Martinez—Romero R, Garcia Del Moral R, Ruiz de Almodovar JM, Villuendas R, Piris MA, and Oliver FJ. Inhibition of poly(ADP-ribose) polymerase modulates tumor-related gene expression, including hypoxia-inducible factor-1 activation, during skin carcinogenesis. *Cancer Res* 66: 5744–5756, 2006.
188. Martin PR, Shea RJ, and Mulks MH. Identification of a plasmid-encoded gene from *Haemophilus ducreyi* which confers NAD independence. *J Bacteriol* 183: 1168–1174, 2001.
189. Marzulli D, La Piana G, Fransvea E, and Lofrumento NE. Modulation of cytochrome c-mediated extramitochondrial NADH oxidation by contact site density. *Biochem Biophys Res Commun* 259: 325–330, 1999.
190. Mattson MP. Calcium as sculptor and destroyer of neural circuitry. *Exp Gerontol* 27: 29–49, 1992.
191. Maynard KI, Ayoub IA, and Shen CC. Delayed multidose treatment with nicotinamide extends the degree and duration of neuroprotection by reducing infarction and improving behavioral scores up to two weeks following transient focal cerebral ischemia in Wistar rats. *Ann NY Acad Sci* 939: 416–424, 2001.
192. Mazzio EA and Soliman KF. Cytoprotection of pyruvic acid and reduced beta-nicotinamide adenine dinucleotide against hydrogen peroxide toxicity in neuroblastoma cells. *Neurochem Res* 28: 733–741, 2003.
193. McCormack JG and Denton RM. The role of Ca<sup>2+</sup> in the regulation of intramitochondrial energy production in heart. *Biomed Biochim Acta* 46: S487–492, 1987.
194. McGuinness ET and Butler JR. NAD<sup>+</sup> kinase—a review. *Int J Biochem* 17: 1–11, 1985.
195. McKenna MC, Waagepetersen HS, Schousboe A, and Sorenwald U. Neuronal and astrocytic shuttle mechanisms for cytosolic-mitochondrial transfer of reducing equivalents: Current evidence and pharmacological tools. *Biochem Pharmacol* 71: 399–407, 2006.
196. Meischl C, Krijnen PA, Sipkens JA, Cillessen SA, Munoz IG, Okroj M, Ramska M, Muller A, Visser CA, Musters RJ, Simonides WS, Hack CE, Roos D, and Niessen HW. Ischemia induces nuclear NOX2 expression in cardiomyocytes and subsequently activates apoptosis. *Apoptosis* 11: 913–921, 2006.
197. Meisterernst M, Stelzer G, and Roeder RG. Poly(ADP-ribose) polymerase enhances activator-dependent transcription in vitro. *Proc Natl Acad Sci USA* 94: 2261–2265, 1997.
198. Meyer RG, Meyer—Ficca ML, Jacobson EL, and Jacobson MK. Human poly(ADP-ribose) glycohydrolase (PARG) gene and the common promoter sequence it shares with inner mitochondrial membrane translocase 23 (TIM23). *Gene* 314: 181–190, 2003.
199. Mhatre M, Floyd RA, and Hensley K. Oxidative stress and neuroinflammation in Alzheimer's disease and amyotrophic lateral sclerosis: common links and potential therapeutic targets. *J Alzheimers Dis* 6: 147–157, 2004.
200. Michan S and Sinclair D. Sirtuins in mammals: insights into their biological function. *Biochem J* 404: 1–13, 2007.
201. Minich T, Yokota S, and Dringen R. Cytosolic and mitochondrial isoforms of NADP<sup>+</sup>-dependent isocitrate dehydrogenases are expressed in cultured rat neurons, astrocytes, oligodendrocytes and microglial cells. *J Neurochem* 86: 605–614, 2003.
202. Modjtahedi N, Giordanetto F, Madeo F, and Kroemer G. Apoptosis-inducing factor: vital and lethal. *Trends Cell Biol* 16: 264–272, 2006.
203. Mokudai T, Ayoub IA, Sakakibara Y, Lee EJ, Ogilvy CS, and Maynard KI. Delayed treatment with nicotinamide (Vitamin B(3)) improves neurological outcome and reduces infarct volume after transient focal cerebral ischemia in Wistar rats. *Stroke* 31: 1679–1685, 2000.
204. Moreira PI, Honda K, Liu Q, Santos MS, Oliveira CR, Aliev G, Nunomura A, Zhu X, Smith MA, and Perry G. Oxidative stress: the old enemy in Alzheimer's disease pathophysiology. *Curr Alzheimer Res* 2: 403–408, 2005.
205. Moreno MU, Jose GS, Fortuno A, Beloqui O, Diez J, and Zalba G. The C242T CYBA polymorphism of NADPH oxidase is associated with essential hypertension. *J Hypertens* 24: 1299–1306, 2006.
206. Moroni F. Tryptophan metabolism and brain function: focus on kynurenine and other indole metabolites. *Eur J Pharmacol* 375: 87–100, 1999.
207. Morrison AD, Clements RS, Jr., and Winegrad AI. Effects of elevated glucose concentrations on the metabolism of the aortic wall. *J Clin Invest* 51: 3114–3123, 1972.
208. Mostoslavsky R, Chua KF, Lombard DB, Pang WW, Fischer MR, Gellon L, Liu P, Mostoslavsky G, Franco S, Murphy MM, Mills KD, Patel P, Hsu JT, Hong AL, Ford E, Cheng HL, Kennedy C, Nunez N, Bronson R, Frenthewey D, Auerbach W, Valenzuela D, Karow M, Hottiger MO, Hursting S, Barrett JC, Guarente L, Mulligan R, Demple B, Yancopoulos GD, and Alt FW. Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. *Cell* 124: 315–329, 2006.
209. Motta MC, Divecha N, Lemieux M, Kamel C, Chen D, Gu W, Bultsma Y, McBurney M, and Guarente L. Mammalian SIRT1 represses forkhead transcription factors. *Cell* 116: 551–563, 2004.
210. Mukherjee SK, Klaidman LK, Yasharel I, and Adams JD, Jr. Increased brain NAD prevents neuronal apoptosis in vivo. *Eur J Pharmacol* 330: 27–34, 1997.
211. Murdoch CE, Zhang M, Cave AC, and Shah AM. NADPH oxidase-dependent redox signalling in cardiac hypertrophy, remodeling and failure. *Cardiovasc Res* 71: 208–215, 2006.
212. Muth V, Nadaud S, Grummt I, and Voit R. Acetylation of TAF(I)68, a subunit of TIF-IB/SL1, activates RNA polymerase I transcription. *EMBO J* 20: 1353–1362, 2001.
213. Nadlinger K, Birkmayer J, Gebauer F, and Kunze R. Influence of reduced nicotinamide adenine dinucleotide on the production of



- interleukin-6 by peripheral human blood leukocytes. *Neuroimmunomodulation* 9: 203–208, 2001.
214. Nakae J, Cao Y, Daitoku H, Fukamizu A, Ogawa W, Yano Y, and Hayashi Y. The LXXLL motif of murine forkhead transcription factor FoxO1 mediates Sirt1-dependent transcriptional activity. *J Clin Invest* 116: 2473–2483, 2006.
215. Neuburger M and Douce R. Slow passive diffusion of NAD<sup>+</sup> between intact isolated plant mitochondria and suspending medium. *Biochem J* 216: 443–450, 1983.
216. North RA and Barnard EA. Nucleotide receptors. *Curr Opin Neurobiol* 7: 346–357, 1997.
217. Oei SL, Griesenbeck J, Schweiger M, and Ziegler M. Regulation of RNA polymerase II-dependent transcription by poly(ADP-ribose)ylation of transcription factors. *J Biol Chem* 273: 31644–31647, 1998.
218. Oei SL, Griesenbeck J, Ziegler M, and Schweiger M. A novel function of poly(ADP-ribose)ylation: silencing of RNA polymerase II-dependent transcription. *Biochemistry* 37: 1465–1469, 1998.
219. Ohashi S, Kanai M, Hanai S, Uchiumi F, Maruta H, Tanuma S, and Miwa M. Subcellular localization of poly(ADP-ribose) glycohydrolase in mammalian cells. *Biochem Biophys Res Commun* 307: 915–921, 2003.
220. Olek RA, Ziolkowski W, Kaczor JJ, Greci L, Popinigis J, and Antosiewicz J. Antioxidant activity of NADH and its analogue—an in vitro study. *J Biochem Mol Biol* 37: 416–421, 2004.
221. Outten CE and Culotta VC. A novel NADH kinase is the mitochondrial source of NADPH in *Saccharomyces cerevisiae*. *EMBO J* 22: 2015–2024, 2003.
222. Pagans S, Pedal A, North BJ, Kaehlcke K, Marshall BL, Dorr A, Hetzer—Egger C, Henklein P, Frye R, McBurney MW, Hruby H, Jung M, Verdin E, and Ott M. SIRT1 regulates HIV transcription via Tat deacetylation. *PLoS Biol* 3: e41, 2005.
223. Pandolfi PP, Sonati F, Rivi R, Mason P, Grosveld F, and Luzatto L. Targeted disruption of the housekeeping gene encoding glucose 6-phosphate dehydrogenase (G6PD): G6PD is dispensable for pentose synthesis but essential for defense against oxidative stress. *EMBO J* 14: 5209–5215, 1995.
224. Pardo B, Contreras L, Serrano A, Ramos M, Kobayashi K, Iijima M, Saheki T, and Satrustegui J. Essential role of aralar in the transduction of small Ca<sup>2+</sup> signals to neuronal mitochondria. *J Biol Chem* 281: 1039–1047, 2006.
225. Partida—Sanchez S, Cockayne DA, Monard S, Jacobson EL, Oppenheimer N, Garvy B, Kusser K, Goodrich S, Howard M, Harmen A, Randall TD, and Lund FE. Cyclic ADP-ribose production by CD38 regulates intracellular calcium release, extracellular calcium influx and chemotaxis in neutrophils and is required for bacterial clearance in vivo. *Nat Med* 7: 1209–1216, 2001.
226. Partida—Sanchez S, Randall TD, and Lund FE. Innate immunity is regulated by CD38, an ecto-enzyme with ADP-ribosyl cyclase activity. *Microbes Infect* 5: 49–58, 2003.
227. Patel NS, Cortes U, Di Poala R, Mazzon E, Mota—Filipe H, Cuzocrea S, Wang ZQ, and Thiemermann C. Mice lacking the 110-kD isoform of poly(ADP-ribose) glycohydrolase are protected against renal ischemia/reperfusion injury. *J Am Soc Nephrol* 16: 712–719, 2005.
228. Patterson RL, van Rossum DB, Kaplin AI, Barrow RK, and Snyder SH. Inositol 1,4,5-trisphosphate receptor/GAPDH complex augments Ca<sup>2+</sup> release via locally derived NADH. *Proc Natl Acad Sci USA* 102: 1357–1359, 2005.
229. Pieper AA, Brat DJ, Krug DK, Watkins CC, Gupta A, Blackshaw S, Verma A, Wang ZQ, and Snyder SH. Poly(ADP-ribose) polymerase-deficient mice are protected from streptozotocin-induced diabetes. *Proc Natl Acad Sci USA* 96: 3059–3064, 1999.
230. Pieper AA, Verma A, Zhang J, and Snyder SH. Poly (ADP-ribose) polymerase, nitric oxide and cell death. *Trends Pharmacol Sci* 20: 171–181, 1999.
231. Pillai JB, Isbatan A, Imai S, and Gupta MP. Poly(ADP-ribose) polymerase-1-dependent cardiac myocyte cell death during heart failure is mediated by NAD<sup>+</sup> depletion and reduced Sir2alpha deacetylase activity. *J Biol Chem* 280: 43121–43130, 2005.
232. Poirier GG, de Murcia G, Jongstra-Bilen J, Niedergang C, and Mandel P. Poly(ADP-ribose)ylation of polynucleosomes causes relaxation of chromatin structure. *Proc Natl Acad Sci USA* 79: 3423–3427, 1982.
233. Pollak N, Dolle C, and Ziegler M. The power to reduce: pyridine nucleotides—small molecules with a multitude of functions. *Biochem J* 402: 205–218, 2007.
234. Przedborski S, Jackson—Lewis V, Djaldetti R, Liberatore G, Vila M, Vukosavic S, and Almer G. The parkinsonian toxin MPTP: action and mechanism. *Restor Neurol Neurosci* 16: 135–142, 2000.
235. Raffaelli N, Sorci L, Amici A, Emanuelli M, Mazzola F, and Magni G. Identification of a novel human nicotinamide mononucleotide adenylyltransferase. *Biochem Biophys Res Commun* 297: 835–840, 2002.
236. Reale A, Matteis GD, Galleazzi G, Zampieri M, and Caiapa P. Modulation of DNMT1 activity by ADP-ribose polymers. *Oncogene* 24: 13–19, 2005.
237. Revollo JR, Grimm AA, and Imai S. The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. *J Biol Chem* 279: 50754–50763, 2004.
238. Revollo JR, Grimm AA, and Imai S. The regulation of nicotinamide adenine dinucleotide biosynthesis by Namp1/PBEF/visfatin in mammals. *Curr Opin Gastroenterol* 23: 164–170, 2007.
239. Rey FE, Cifuentes ME, Kiarash A, Quinn MT, and Pagano PJ. Novel competitive inhibitor of NAD(PH) oxidase assembly attenuates vascular O<sub>2</sub><sup>-</sup> and systolic blood pressure in mice. *Circ Res* 89: 408–414, 2001.
240. Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, and Puigserver P. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. *Nature* 434: 113–118, 2005.
241. Rongvaux A, Shea RJ, Mulks MH, Gigot D, Urbain J, Leo O, and Andris F. Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. *Eur J Immunol* 32: 3225–3234, 2002.
242. Ronnebaum SM, Ilkayeva O, Burgess SC, Joseph JW, Lu D, Stevens RD, Becker TC, Sherry AD, Newgard CB, and Jensen MV. A pyruvate cycling pathway involving cytosolic NADP-dependent isocitrate dehydrogenase regulates glucose-stimulated insulin secretion. *J Biol Chem* 281: 30593–30602, 2006.
243. Rossi L, Denegri M, Torti M, Poirier GG, and Ivana Scovassi A. Poly(ADP-ribose) degradation by post-nuclear extracts from human cells. *Biochimie* 84: 1229–1235, 2002.
244. Rustin P, Parfait B, Chretien D, Bourgeron T, Djouadi F, Bastin J, Rotig A, and Munnich A. Fluxes of nicotinamide adenine dinucleotides through mitochondrial membranes in human cultured cells. *J Biol Chem* 271: 14785–14790, 1996.
245. Rutter J, Reick M, Wu LC, and McKnight SL. Regulation of clock and NPAS2 DNA binding by the redox state of NAD cofactors. *Science* 293: 510–514, 2001.
246. Rydstrom J. Mitochondrial NADPH, transhydrogenase and disease. *Biochim Biophys Acta* 1757: 721–726, 2006.
247. Ryter SW, Kim HP, Hoetzel A, Park JW, Nakahira K, Wang X, and Choi AM. Mechanisms of cell death in oxidative stress. *Antioxid Redox Signal* 9: 49–89, 2007.
248. Samal B, Sun Y, Stearns G, Xie C, Suggs S, and McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. *Mol Cell Biol* 14: 1431–1437, 1994.
249. Sapko MT, Guidetti P, Yu P, Tagle DA, Pellicciari R, and Schwarcz R. Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: Implications for Huntington's disease. *Exp Neurol* 197: 31–40, 2006.
250. Sauve AA, Wolberger C, Schramm VL, and Boeke JD. The Biochemistry of Sirtuins. *Annu Rev Biochem* 75: 435–465, 2006.
251. Savina A, Jancic C, Hugues S, Guermonez P, Vargas P, Moura IC, Lennon—Dumenil AM, Seabra MC, Raposo G, and Amigorena S. NOX2 controls phagosomal pH to regulate antigen processing during crosspresentation by dendritic cells. *Cell* 126: 205–218, 2006.
252. Sawa A, Khan AA, Hester LD, and Snyder SH. Glyceraldehyde-3-phosphate dehydrogenase: nuclear translocation participates in

- neuronal and nonneuronal cell death. *Proc Natl Acad Sci USA* 94: 11669–11674, 1997.
253. Sazanov LA and Jackson JB. Proton-translocating transhydrogenase and NAD- and NADP-linked isocitrate dehydrogenases operate in a substrate cycle which contributes to fine regulation of the tricarboxylic acid cycle activity in mitochondria. *FEBS Lett* 344: 109–116, 1994.
  254. Schreiber V, Dantzer F, Ame JC, and de Murcia G. Poly(ADP-ribose): novel functions for an old molecule. *Nat Rev Mol Cell Biol* 7: 517–528, 2006.
  255. Schwarcz R and Pellicciari R. Manipulation of brain kynurenes: glial targets, neuronal effects, and clinical opportunities. *J Pharmacol Exp Ther* 303: 1–10, 2002.
  256. Schwartz AG and Pashko LL. Dehydroepiandrosterone, glucose-6-phosphate dehydrogenase, and longevity. *Ageing Res Rev* 3: 171–187, 2004.
  257. Schwer B, Bunkenborg J, Verdin RO, Andersen JS, and Verdin E. Reversible lysine acetylation controls the activity of the mitochondrial enzyme acetyl-CoA synthetase 2. *Proc Natl Acad Sci USA* 103: 10224–10229, 2006.
  258. Scott MD, Zuo L, Lubin BH, and Chiu DT. NADPH, not glutathione, status modulates oxidant sensitivity in normal and glucose-6-phosphate dehydrogenase-deficient erythrocytes. *Blood* 77: 2059–2064, 1991.
  259. Seimiya H, Muramatsu Y, Ohishi T, and Tsuruo T. Tankyrase 1 as a target for telomere-directed molecular cancer therapeutics. *Cancer Cell* 7: 25–37, 2005.
  260. Seimiya H. The telomeric PARP, tankyrases, as targets for cancer therapy. *Br J Cancer* 94: 341–345, 2006.
  261. Seman M, Adriouch S, Haag F, and Koch—Nolte F. Ecto-ADP-ribosyltransferases (ARTs): emerging actors in cell communication and signaling. *Curr Med Chem* 11: 857–872, 2004.
  262. Sen CK and Packer L. Antioxidant and redox regulation of gene transcription. *FASEB J* 10: 709–720, 1996.
  263. Sen CK. Cellular thiols and redox-regulated signal transduction. *Curr Top Cell Regul* 36: 1–30, 2000.
  264. Shianna KV, Marchuk DA, and Strand MK. Genomic characterization of POS5, the *Saccharomyces cerevisiae* mitochondrial NADH kinase. *Mitochondrion* 6: 94–101, 2006.
  265. Shigenaga MK, Hagen TM, and Ames BN. Oxidative damage and mitochondrial decay in aging. *Proc Natl Acad Sci USA* 91: 10771–10778, 1994.
  266. Shimohama S, Tanino H, Kawakami N, Okamura N, Kodama H, Yamaguchi T, Hayakawa T, Nunomura A, Chiba S, Perry G, Smith MA, and Fujimoto S. Activation of NADPH oxidase in Alzheimer's disease brains. *Biochem Biophys Res Commun* 273: 5–9, 2000.
  267. Shin AH, Kil IS, Yang ES, Huh TL, Yang CH, and Park JW. Regulation of high glucose-induced apoptosis by mitochondrial NADP<sup>+</sup>-dependent isocitrate dehydrogenase. *Biochem Biophys Res Commun* 325: 32–38, 2004.
  268. Sivilotti ML. Oxidant stress and haemolysis of the human erythrocyte. *Toxicol Rev* 23: 169–188, 2004.
  269. Slekar KH, Kosman DJ, and Culotta VC. The yeast copper/zinc superoxide dismutase and the pentose phosphate pathway play overlapping roles in oxidative stress protection. *J Biol Chem* 271: 28831–28836, 1996.
  270. Smogorzewska A and de Lange T. Regulation of telomerase by telomeric proteins. *Annu Rev Biochem* 73: 177–208, 2004.
  271. Soane L, Kahraman S, Kristian T, and Fiskum G. Mechanisms of impaired mitochondrial energy metabolism in acute and chronic neurodegenerative disorders. *J Neurosci Res* 2007 (Epub ahead of print).
  272. Sohal RS. The free radical hypothesis of aging: an appraisal of the current status. *Ageing (Milano)* 5: 3–17, 1993.
  273. Starai VJ, Celic I, Cole RN, Boeke JD, and Escalante—Semerena JC. Sir2-dependent activation of acetyl-CoA synthetase by deacetylation of active lysine. *Science* 298: 2390–2392, 2002.
  274. Starkov AA, Fiskum G, Chinopoulos C, Lorenzo BJ, Browne SE, Patel MS, and Beal MF. Mitochondrial alpha-ketoglutarate dehydrogenase complex generates reactive oxygen species. *J Neurosci* 24: 7779–7788, 2004.
  275. Strumilo E. Effect of Ca<sup>2+</sup> on the activity of mitochondrial NADP-specific isocitrate dehydrogenase from rabbit adrenals. *Acta Biochim Pol* 42: 325–328, 1995.
  276. Stubbs M, Veech RL, and Krebs HA. Control of the redox state of the nicotinamide-adenine dinucleotide couple in rat liver cytoplasm. *Biochem J* 126: 59–65, 1972.
  277. Suh SW, Aoyama K, Chen Y, Garnier P, Matsumori Y, Gum E, Liu J, and Swanson RA. Hypoglycemic neuronal death and cognitive impairment are prevented by poly(ADP-ribose) polymerase inhibitors administered after hypoglycemia. *J Neurosci* 23: 10681–10690, 2003.
  278. Suh SW, Aoyama K, Matsumori Y, Liu J, and Swanson RA. Pyruvate administered after severe hypoglycemia reduces neuronal death and cognitive impairment. *Diabetes* 54: 1452–1458, 2005.
  279. Szabo C and Dawson VL. Role of poly(ADP-ribose) synthetase in inflammation and ischaemia-reperfusion. *Trends Pharmacol Sci* 19: 287–298, 1998.
  280. Tirone F and Cox JA. NADPH oxidase 5 (NOX5) interacts with and is regulated by calmodulin. *FEBS Lett* 581: 1202–1208, 2007.
  281. Tobin A, Djerdjour B, Journet E, Neuburger M, and Douce R. Effect of NAD on Malate Oxidation in Intact Plant Mitochondria. *Plant Physiol* 66: 225–229, 1980.
  282. Todisco S, Agrimi G, Castegna A, and Palmieri F. Identification of the mitochondrial NAD<sup>+</sup> transporter in *Saccharomyces cerevisiae*. *J Biol Chem* 281: 1524–1531, 2006.
  283. Tokime T, Nozaki K, Sugino T, Kikuchi H, Hashimoto N, and Ueda K. Enhanced poly(ADP-ribosylation) after focal ischemia in rat brain. *J Cereb Blood Flow Metab* 18: 991–997, 1998.
  284. Toye AA, Lippiat JD, Proks P, Shimomura K, Bentley L, Hugill A, Mijat V, Goldsworthy M, Moir L, Haynes A, Quarterman J, Freeman HC, Ashcroft FM, and Cox RD. A genetic and physiological study of impaired glucose homeostasis control in C57BL/6J mice. *Diabetologia* 48: 675–686, 2005.
  285. Tulin A, Naumova NM, Menon AK, and Spradling AC. *Drosophila* poly(ADP-ribose) glycohydrolase mediates chromatin structure and SIR2-dependent silencing. *Genetics* 172: 363–371, 2006.
  286. Tzagoloff AM. *Mitochondria*. Plenum Press, New York, p. 1., 1982.
  287. Uchiumi F, Ikeda D, and Tanuma S. Changes in the activities and gene expressions of poly(ADP-ribose) glycohydrolases during the differentiation of human promyelocytic leukemia cell line HL-60. *Biochim Biophys Acta* 1676: 1–11, 2004.
  288. Ushio—Fukai M. Localizing NADPH oxidase-derived ROS. *Sci STKE* 2006: re8, 2006.
  289. Ushio—Fukai M. Redox signaling in angiogenesis: role of NADPH oxidase. *Cardiovasc Res* 71: 226–235, 2006.
  290. Vahsen N, Cande C, Briere JJ, Benit P, Joza N, Larochette N, Mastroberardino PG, Pequignot MO, Casares N, Lazar V, Feraud O, Debili N, Wissing S, Engelhardt S, Madeo F, Piacentini M, Penninger JM, Schagger H, Rustin P, and Kroemer G. AIF deficiency compromises oxidative phosphorylation. *EMBO J* 23: 4679–4689, 2004.
  291. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, and Telser J. Free radicals and antioxidants in normal physiological functions and human disease. *Int J Biochem Cell Biol* 39: 44–84, 2007.
  292. van der Veer E, Nong Z, O'Neil C, Urquhart B, Freeman D, and Pickering JG. Pre-B-cell colony-enhancing factor regulates NAD<sup>+</sup>-dependent protein deacetylase activity and promotes vascular smooth muscle cell maturation. *Circ Res* 97: 25–34, 2005.
  293. van der Veer E, Ho C, O'Neil C, Barbosa N, Scott R, Cregan SP, and Pickering JG. Extension of human cell lifespan by nicotinamide phosphoribosyltransferase. *J Biol Chem* 282: 10841–10845, 2007.
  294. Veech RL, Eggleston LV, and Krebs HA. The redox state of free nicotinamide-adenine dinucleotide phosphate in the cytoplasm of rat liver. *Biochem J* 115: 609–619, 1969.
  295. Verderio C, Bruzzone S, Zocchi E, Fedele E, Schenk U, De Flora A, and Matteoli M. Evidence of a role for cyclic ADP-ribose in calcium signalling and neurotransmitter release in cultured astrocytes. *J Neurochem* 78: 646–657., 2001.
  296. Virag L and Szabo C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. *Pharmacol Rev* 54: 375–429, 2002.
  297. Vogel R, Wiesinger H, Hamprecht B, and Dringen R. The regeneration of reduced glutathione in rat forebrain mitochondria identifies metabolic pathways providing the NADPH required. *Neurosci Lett* 275: 97–100, 1999.

298. von Kobbe C, Harrigan JA, May A, Opresko PL, Dawut L, Cheng WH, and Bohr VA. Central role for the Werner syndrome protein/poly(ADP-ribose) polymerase 1 complex in the poly(ADP-ribose)ylation pathway after DNA damage. *Mol Cell Biol* 23: 8601–8613, 2003.
299. von Kobbe C, Harrigan JA, Schreiber V, Stiegler P, Piotrowski J, Dawut L, and Bohr VA. Poly(ADP-ribose) polymerase 1 regulates both the exonuclease and helicase activities of the Werner syndrome protein. *Nucleic Acids Res* 32: 4003–4014, 2004.
300. Walder CE, Green SP, Darbonne WC, Mathias J, Rae J, Dinauer MC, Curnutte JT, and Thomas GR. Ischemic stroke injury is reduced in mice lacking a functional NADPH oxidase. *Stroke* 28: 2252–2258, 1997.
301. Wang BW, Liao WN, Chang CT, and Wang SJ. Facilitation of glutamate release by nicotine involves the activation of a  $Ca^{2+}$ /calmodulin signaling pathway in rat prefrontal cortex nerve terminals. *Synapse* 59: 491–501, 2006.
302. Wang J, Zhai Q, Chen Y, Lin E, Gu W, McBurney MW, and He Z. A local mechanism mediates NAD-dependent protection of axon degeneration. *J Cell Biol* 170: 349–355, 2005.
303. Wang Q, Tompkins KD, Simonyi A, Korthuis RJ, Sun AY, and Sun GY. Apocynin protects against global cerebral ischemia-reperfusion-induced oxidative stress and injury in the gerbil hippocampus. *Brain Res* 1090: 182–189, 2006.
304. Waypa GB and Schumacker PT. Hypoxic pulmonary vasoconstriction: redox events in oxygen sensing. *J Appl Physiol* 98: 404–414, 2005.
305. Wei G, Wang D, Lu H, Parmentier S, Wang Q, Panter SS, Frey WH, 2nd, and Ying W. Intranasal administration of a PARG inhibitor profoundly decreases ischemic brain injury. *Front Biosci* 12: 4986–4996, 2007.
306. Williams MB and Jones HP. Calmodulin-dependent NAD kinase of human neutrophils. *Arch Biochem Biophys* 237: 80–87, 1985.
307. Wolin MS, Ahmad M, and Gupte SA. Oxidant and redox signaling in vascular oxygen sensing mechanisms: basic concepts, current controversies, and potential importance of cytosolic NADPH. *Am J Physiol Lung Cell Mol Physiol* 289: L159–173, 2005.
308. Wolozin B and Golts N. Iron and Parkinson's disease. *Neuroscientist* 8: 22–32, 2002.
309. Wu G, Fang YZ, Yang S, Lupton JR, and Turner ND. Glutathione metabolism and its implications for health. *J Nutr* 134: 489–492, 2004.
310. Xu Y, Huang S, Liu ZG, and Han J. Poly(ADP-ribose) polymerase-1 signaling to mitochondria in necrotic cell death requires RIP1/TRAF2-mediated JNK1 activation. *J Biol Chem* 281: 8788–8795, 2006.
311. Yakovlev AG, Wang G, Stoica BA, Boulares HA, Spoonde AY, Yoshihara K, and Smulson ME. A role of the  $Ca^{2+}/Mg^{2+}$ -dependent endonuclease in apoptosis and its inhibition by poly(ADP-ribose) polymerase. *J Biol Chem* 275: 21302–21308, 2000.
312. Yang J, Klaidman LK, Nalbandian A, Oliver J, Chang ML, Chan PH, and Adams JD, Jr. The effects of nicotinamide on energy metabolism following transient focal cerebral ischemia in Wistar rats. *Neurosci Lett* 333: 91–94, 2002.
313. Yang JH, Yang ES, and Park JW. Inactivation of NADP<sup>+</sup>-dependent isocitrate dehydrogenase by lipid peroxidation products. *Free Radic Res* 38: 241–249, 2004.
314. Yang KT, Chang WL, Yang PC, Chien CL, Lai MS, Su MJ, and Wu ML. Activation of the transient receptor potential M2 channel and poly(ADP-ribose) polymerase is involved in oxidative stress-induced cardiomyocyte death. *Cell Death Differ*, 2005.
315. Yang Z, Zhang H, Hung HC, Kuo CC, Tsai LC, Yuan HS, Chou WY, Chang GG, and Tong L. Structural studies of the pigeon cytosolic NADP<sup>(+)</sup>-dependent malic enzyme. *Protein Sci* 11: 332–341, 2002.
316. Yelamos J, Monreal Y, Saenz L, Aguado E, Schreiber V, Mota R, Fuente T, Minguela A, Parrilla P, de Murcia G, Almarza E, Aparicio P, and Menissier-de Murcia J. PARP-2 deficiency affects the survival of CD4<sup>+</sup>CD8<sup>+</sup> double-positive thymocytes. *EMBO J* 25: 4350–4360, 2006.
317. Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, Frye RA, and Mayo MW. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. *EMBO J* 23: 2369–2380, 2004.
318. Ying W. Deleterious network hypothesis of Alzheimer's disease. *Med Hypotheses* 46: 421–428, 1996.
319. Ying W. A new hypothesis of neurodegenerative diseases: the deleterious network hypothesis. *Med Hypotheses* 47: 307–313, 1996.
320. Ying W. Deleterious network: a testable pathogenetic concept of Alzheimer's disease. *Gerontology* 43: 242–253, 1997.
321. Ying W. Deleterious network hypothesis of aging. *Med Hypotheses* 48: 143–148, 1997.
322. Ying W. Deleterious network hypothesis of apoptosis. *Med Hypotheses* 50: 393–398, 1998.
323. Ying W and Swanson RA. The poly(ADP-ribose) glycohydrolase inhibitor gallotannin blocks oxidative astrocyte death. *Neuroreport* 11: 1385–1388, 2000.
324. Ying W, Sevigny MB, Chen Y, and Swanson RA. Poly(ADP-ribose) glycohydrolase mediates oxidative and excitotoxic neuronal death. *Proc Natl Acad Sci USA* 98: 12227–12232, 2001.
325. Ying W, Chen Y, Alano CC, and Swanson RA. Tricarboxylic acid cycle substrates prevent PARP-mediated death of neurons and astrocytes. *J Cereb Blood Flow Metab* 22: 774–779, 2002.
326. Ying W, Garnier P, and Swanson RA. NAD<sup>+</sup> repletion prevents PARP-1-induced glycolytic blockade and cell death in cultured mouse astrocytes. *Biochem Biophys Res Commun* 308: 809–813, 2003.
327. Ying W, Alano CC, Garnier P, and Swanson RA. NAD<sup>+</sup> as a metabolic link between DNA damage and cell death. *J Neurosci Res* 79: 216–223, 2005.
328. Ying W. NAD<sup>+</sup> and NADH in cellular functions and cell death. *Front Biosci* 11: 3129–3148, 2006.
329. Ying W. NAD<sup>+</sup> and NADH in brain functions, brain diseases and brain aging. *Front Biosci* 12: 1863–1888, 2007.
330. Ying W, Wei G, Wang D, Shi J, and Lu H. Intranasal administration of NAD<sup>+</sup> and the PARG inhibitor gallotannin can decrease both ischemic oxygen sensing mechanisms and traumatic brain injury. *37th American Society for Neuroscience Annual Meeting Abstracts*, 2007.
331. Ying W. Therapeutic potential of NAD<sup>+</sup> for treating neurological diseases. *Future Neurol* 2: 129–132, 2007.
332. Yu SW, Wang H, Poitras MF, Coombs C, Bowers WJ, Federoff HJ, Poirier GG, Dawson TM, and Dawson VL. Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. *Science* 297: 259–263, 2002.
333. Yu SW, Andrabi SA, Wang H, Kim NS, Poirier GG, Dawson TM, and Dawson VL. Apoptosis-inducing factor mediates poly(ADP-ribose) (PAR) polymer-induced cell death. *Proc Natl Acad Sci USA* 103: 18314–18319, 2006.
334. Yu Z, Kuncewicz T, Dubinsky WP, and Kone BC. Nitric oxide-dependent negative feedback of PARP-1 trans-activation of the inducible nitric-oxide synthase gene. *J Biol Chem* 281: 9101–9109, 2006.
335. Zardo G, D'Erme M, Reale A, Strom R, Perilli M, and Caiafa P. Does poly(ADP-ribose)ylation regulate the DNA methylation pattern? *Biochemistry* 36: 7937–7943, 1997.
336. Zardo G, Marenzi S, Perilli M, and Caiafa P. Inhibition of poly(ADP-ribose)ylation introduces an anomalous methylation pattern in transfected foreign DNA. *FASEB J* 13: 1518–1522, 1999.
337. Zardo G, Reale A, Passananti C, Pradhan S, Buontempo S, De Matteis G, Adams RL, and Caiafa P. Inhibition of poly(ADP-ribose)ylation induces DNA hypermethylation: a possible molecular mechanism. *FASEB J* 16: 1319–1321, 2002.
338. Zeng J, Yang GY, Ying W, Kelly M, Hirai K, James TL, Swanson RA, and Litt L. Pyruvate improves recovery after PARP-1-associated energy failure induced by oxidative stress in neonatal rat cerebrotical slices. *J Cereb Blood Flow Metab* 27: 304–315, 2007.
339. Zerez CR, Moul DE, Gomez EG, Lopez VM, and Andreoli AJ. Negative modulation of *Escherichia coli* NAD kinase by NADPH and NADH. *J Bacteriol* 169: 184–188, 1987.
340. Zhai RG, Cao Y, Hiesinger PR, Zhou Y, Mehta SQ, Schulze KL, Verstreken P, and Bellen HJ. Drosophila NMNAT maintains neural integrity independent of its NAD synthesis activity. *PLoS Biol* 4: e416, 2006.

341. Zhang J, Dawson VL, Dawson TM, and Snyder SH. Nitric oxide activation of poly(ADP-ribose) synthetase in neurotoxicity. *Science* 263: 687–689, 1994.
342. Zhang Q, Piston DW, and Goodman RH. Regulation of corepressor function by nuclear NADH. *Science* 295: 1895–1897, 2002.
343. Zhang S, Lin Y, Kim YS, Hande MP, Liu ZG, and Shen HM. c-Jun N-terminal kinase mediates hydrogen peroxide-induced cell death via sustained poly(ADP-ribose) polymerase-1 activation. *Cell Death Differ* 14: 1001–1010, 2007.
344. Zhang Z, Blake DR, Stevens CR, Kanczler JM, Winyard PG, Symons MC, Benboubetra M, and Harrison R. A reappraisal of xanthine dehydrogenase and oxidase in hypoxic reperfusion injury: the role of NADH as an electron donor. *Free Radic Res* 28: 151–164, 1998.
345. Zhu K, Swanson RA, and Ying W. NADH can enter into astrocytes and block poly(ADP-ribose) polymerase-1-mediated astrocyte death. *Neuroreport* 16: 1209–1212, 2005.
346. Zhu X, Raina AK, Lee HG, Casadesus G, Smith MA, and Perry G. Oxidative stress signalling in Alzheimer's disease. *Brain Res* 1000: 32–39, 2004.
347. Ziegler M. New functions of a long-known molecule. Emerging roles of NAD in cellular signaling. *Eur J Biochem* 267: 1550–1564., 2000.
348. Zima AV, Copello JA, and Blatter LA. Differential modulation of cardiac and skeletal muscle ryanodine receptors by NADH. *FEBS Lett* 547: 32–36, 2003.
349. Zima AV, Copello JA, and Blatter LA. Effects of cytosolic NADH/NAD(+) levels on sarcoplasmic reticulum Ca(2+) release in permeabilized rat ventricular myocytes. *J Physiol* 555: 727–741, 2004.
350. Zong WX, Ditsworth D, Bauer DE, Wang ZQ, and Thompson CB. Alkylating DNA damage stimulates a regulated form of necrotic cell death. *Genes Dev* 18: 1272–1282, 2004.
351. Zong WX and Thompson CB. Necrotic death as a cell fate. *Genes Dev* 20: 1–15, 2006.
352. Zoratti M and Szabo I. The mitochondrial permeability transition. *Biochim Biophys Acta* 1241: 139–176, 1995.

Address reprint requests to:

Wei-hai Ying, Ph.D.

Department of Neurology (127)

San Francisco VA Medical Center and the University of

California at San Francisco

4150 Clement Street

San Francisco, CA 94121

E-mail: Wei-hai.Ying@ucsf.edu

Date of first submission to ARS Central, April 2, 2007; date of final revised submission, July 5, 2007; date of acceptance, September 16, 2007.